

1 **Impaired HA-specific T follicular helper cell and antibody responses to** 2 **influenza vaccination are linked to inflammation in humans.**

3 4 **Authors:**

5 Danika L Hill^{1, 2#}, Silvia Innocentin¹, Jiong Wang³, Eddie A James⁴, James C Lee^{5,6}, William
6 W Kwok^{7,8}, Martin Zand³, Edward J Carr^{1,6}, Michelle A Linterman^{1#}

7
8 ¹ The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK

9 ² Department of Immunology and Pathology, Monash University, Melbourne, Victoria, 3004,
10 Australia

11 ³ Division of Nephrology, Department of Medicine and Clinical and Translational Science
12 Institute, University of Rochester Medical Center, Rochester, NY.

13 ⁴ Benaroya Research Institute at Virginia Mason, Translational Research Program and
14 Tetramer Core Laboratory, Seattle, Washington 98101, USA.

15 ⁵ Cambridge Institute of Therapeutic Immunology & Infectious Disease, Jeffrey Cheah
16 Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, CB2 0AW,
17 UK.

18 ⁶ Dept of Medicine, University of Cambridge, Cambridge Biomedical Campus, Hills Road,
19 Cambridge, CB2 0QQ, UK

20 ⁷ Benaroya Research Institute at Virginia Mason, Diabetes Program, Seattle, Washington
21 98101, USA.

22 ⁸ Department of Medicine, University of Washington, Seattle, Washington 98195, USA

23
24 # Correspondence to Michelle Linterman, michelle.linterman@babraham.ac.uk or Danika
25 Hill, Danika.hill@monash.edu.au

26 27 **One sentence summary**

28 Antibody production upon vaccination requires antigen-specific cTfh cells whose formation
29 is suppressed by pro-inflammatory cytokine signalling.

30
31
32
33 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Abstract:

Antibody production following vaccination can provide protective immunity to subsequent infection from pathogens such as influenza. However, circumstances where antibody formation is impaired after vaccination, such as in older people, require us to better understand the cellular and molecular mechanisms that underpin successful vaccination in order to improve vaccine design for at risk groups. Here, by studying the breadth of anti-hemagglutinin (HA) IgG, serum cytokines, and B and T cell responses by flow cytometry before and after influenza vaccination, we show that formation of circulating T follicular helper cells (cTfh) cells are the best predictor of high titre antibody responses. Using MHC class II tetramers we demonstrate that HA-specific cTfh cells can be derived from pre-existing memory CD4⁺ T cells and have a diverse TCR repertoire. In older people, the differentiation of HA-specific cells into cTfh cells was impaired. This age-dependent defect in cTfh cell formation was not due to a contraction of the TCR repertoire, but rather was linked with an increased inflammatory gene signature in cTfh cells. Together this suggests that strategies that temporarily dampen inflammation at the time of vaccination may be a viable strategy to boost optimal antibody generation upon immunisation of older people.

Introduction:

Vaccination is an excellent intervention to limit the morbidity and mortality caused by infectious disease. Yet, despite their success, most vaccines are not completely effective, and efficacy varies significantly between different vaccines. The seasonal influenza vaccine needs to be administered each year in order to provide protection against the most prevalent circulating influenza strains, but its efficacy typically ranges from 40-80% even when the vaccine is antigenically matched to circulating viruses. This inefficacy contributes to the millions of severe influenza cases and hundreds of thousands of deaths globally (1), which could be potentially prevented by a more effective vaccine.

The reasons that the seasonal influenza vaccine provides protection in some individuals, but not others, have yet to be fully established. Antibodies against the influenza surface glycoprotein haemagglutinin (HA) are capable of limiting infection, and anti-HA antibody titres and inhibitory activity are the most commonly used correlate of protection (2). The human antibody response to influenza vaccination is highly variable, but what causes this inter-individual variation is not well understood. Twin studies estimate that genetics can

1 account for less than 20% of the variation in antibody responses to influenza vaccination,
2 implicating non-heritable factors as key contributing influences (3). Age, sex, chronic viral
3 infections, and non-communicable diseases have all been reported to influence antibody titre
4 following vaccination (4-9), but how these various factors impact immune responses to
5 vaccination have yet to be fully unravelled.

6 The generation of protective humoral immunity is supported by CD4⁺ helper T cells
7 (10), which, like neutralising antibodies, are correlates of protection for influenza infection
8 (11). The majority of work on human T cell responses to influenza vaccination has focussed
9 on T helper type 1 cells, largely because of the relative ease of detecting antigen-specific
10 cytokine-secreting cells upon *ex vivo* peptide restimulation. However, this approach fails to
11 identify T cell types, such as Tfh cells, that do not readily secrete cytokines(12, 13), and
12 therefore our understanding of how the human CD4 T cell response is linked with high titre
13 antibody responses upon vaccination is limited. Here, we use MHC class-II tetramers (14, 15)
14 to directly assess helper T cell responses to the seasonal influenza vaccine. We find that
15 differentiation of antigen-specific circulating T follicular helper (cTfh) cells, but not the total
16 number of HA-specific CD4⁺ T cells, is correlated with high titre antibody production upon
17 vaccination. HA-specific cTfh cells are clonally expanded from memory cells present pre-
18 vaccination, and share a transcriptional profile with human lymph node Tfh cells. Further, we
19 find that in older people there is a specific defect in the formation of cTfh cells upon
20 vaccination. Interestingly, this was not explained by limited T cell receptor diversity of the
21 responding T cells, as is commonly proposed as the cause of poor T cell responses in older
22 people (16, 17). Rather, poor cTfh and antibody responses correlated with an enhanced
23 inflammatory gene signature. Together, this implicates cTfh cells as key mediators of
24 antigen-specific immunity and suggests that vaccine strategies that limit, rather than enhance,
25 the inflammation associated with ageing may be more successful in older individuals.

26 **Results:**

27 **Hemagglutinin-specific CD4⁺ T cells expand and differentiate in response to seasonal** 28 **influenza vaccination.**

29 In order to track influenza HA-specific CD4 T cells directly *ex vivo* we recruited two cohorts
30 of healthy UK individuals between 18-36 years old across two norther hemisphere influenza
31 seasons in 2014/2015 (n=16, median 30.5 years old) and 2016/2017 (n=21, median 25 years
32 old) carrying either *HLADR*0701* or *HLADR*1101* alleles. Blood samples were collected at
33 baseline (d0), seven days (d7), and 42 days after seasonal trivalent influenza vaccination
34

1 (TIV). A total of 53 distinct variables were measured at two or more time-points (n=147 total
2 measures, Fig 1A, Table S1, Figure S1-3). IgG levels increased against all measured HA
3 proteins from the vaccine influenza strains at d7 and d42 (Fig 1B). We analysed post-
4 vaccination time-points (d7 and d42) compared to baseline to identify which immunological
5 parameters were altered by vaccination (Fig. 1C). From our panel of 32 HA proteins, IgG
6 titres to 31 (96%) were altered at day 42 relative to baseline (d0), with the greatest fold
7 changes were observed for HA strains contained in the TIV. These data indicate that vaccine-
8 induced IgG responses were able to partially cross-react across multiple influenza strains
9 (Fig. 1C). The increase in anti-HA antibody titre was coupled with an increase in
10 hemagglutination inhibitory antibodies to A.Cali09, the one influenza A strain contained in
11 the TIV that was shared across the two cohorts (Fig. 1C). Our analysis of 8 cytokines by
12 Luminex identified that 4 cytokines were upregulated (CXCL13, BCMA, APRIL and
13 Osteopontin) and 2 were downregulated (BAFF and TWEAK) at d7 post-vaccination (Fig.
14 1C, S4). We did not detect alterations in the frequency of any B cell subsets either cohort by
15 flow cytometry, however the frequency of cTfh cells (CD45RA⁻CXCR5⁺PD1⁺⁺) was
16 increased on d7, a population that we and others have previously shown share transcriptional
17 and clonal similarity with germinal centre Tfh cells (18-21). Furthermore, the expression of
18 ICOS on cTfh cells was increased on d7, confirming the cTfh population is an activated
19 effector population that forms in response to vaccination (Fig. 1C, S4).

20
21 To study HA-specific CD4⁺ T cell responses, we focussed our analysis on the A.Cali09 strain
22 as this was included in both seasons' vaccine formulations, and used MHC Class II tetramers
23 of HLADR*0701 and HLADR*1101 loaded with A.Cali09 HA peptides to identify antigen-
24 specific T cells (15). Tetramer binding antigen-experienced CD4⁺CD45RA⁻ (Tet⁺) T cells
25 showed the largest fold-change increase after vaccination of any parameter measured (Fig.
26 1C). Tet⁺ cells were detected in all individuals before vaccination and expanded a median of
27 5-11-fold between d0 and d7 in both cohorts (Fig. 1D, E). These antigen-specific T cells had
28 upregulated ICOS after immunisation, indicating that they have been activated by vaccination
29 (Fig. 1F, G). In addition, one third of HA-specific T cells upregulated the Tfh markers
30 CXCR5 and PD1 seven days after immunisation (Fig. 1H, I), the majority of which expressed
31 CXCR3 (Fig. S5), consistent with the "Th1" skew in the total CD4⁺ T cell (15) and cTfh cell
32 response to influenza vaccination (22). Therefore, seasonal influenza vaccination increases
33 anti-HA IgG titres, induces a cTfh response, and promotes the expansion and differentiation
34 of HA-specific CD4⁺ T cells.

1

2 **Circulating HA-specific Tfh cells correlate with vaccine IgG response.**

3 The majority of successful vaccines provide protection against re-infection through the
4 production of antibodies. The development of antibody secreting plasma cells requires a
5 concerted effort of multiple cell types of the immune system, which have been investigated in
6 detail in mice, but not well in humans. Therefore we sought to determine which immune
7 parameters were linked with A.Cali09 IgG titre six weeks post-vaccination (Fig. 2A-D). Pre-
8 existing antibody titres have been linked with diminished responses to subsequent
9 vaccination (23-25), but while we observed a slight negative correlation at d0 in support of
10 this, the relationship was not statistically significant for any of the Flu HA Luminex or
11 A.Cali09 HAI titres (Fig. 2B). In contrast, the IgG responses to a range of HA proteins from
12 different influenza strains correlated strongly with A.Cali09 IgG (d42-d0), indicating that
13 those individuals with large vaccine-induced IgG responses also developed cross-reactive
14 antibodies against multiple strains (Fig. 2B). Changes between d0 and d7 in serum BCMA
15 was positively correlated, and BAFF negatively correlated with A.Cali09 IgG (d42-d0)
16 responses, in both cohorts (Fig. 2C, E). The frequency of B cell subsets, including antibody
17 secreting cells at d7 was not associated with day 42 A.Cali09 IgG (d42-d0), whereas cTfh
18 cell frequency correlated with antibodies in both cohorts (Fig. 2D, E). A reproducible
19 positive correlation was observed between A.Cali09 IgG (d42-d0) and HA-specific cTfh cells
20 (Fig. 2D, E), but not for total Tet⁺ CD4⁺ T cells (Fig. 2D). This indicates that the
21 differentiation of antigen-specific Tfh cells is more relevant for antibody responses than the
22 overall frequency of antigen-specific helper T cells.

23

24 **HA-specific cTfh response to influenza vaccination includes recalled and public TCR** 25 **clonotypes.**

26 Our results demonstrated that HA-specific cTfh cells are correlated with the antibody
27 response to seasonal influenza vaccination, and so we next investigated how vaccination
28 influences the T cell receptor (TCR) repertoire and transcriptional signatures of HA-specific
29 cTfh cells and their precursors. We sort-purified and RNA sequenced tetramer-binding CD4⁺
30 T cells (Tet⁺ cells) from d0 and Tet⁺ cTfh cells from d7 (Fig. 3A, S3, S6), and retrieved a
31 total of 1405 and 2085 TCRβ clonotypes at d0 and d7, respectively. Expanded clones were
32 observed on d7 (Fig. 3B), resulting in a decrease in the diversity of the TCR repertoire at d7
33 relative to d0 (Fig. 3C), and an increase in the number of co-dominant TCRβ clonotypes

1 within the HA-specific TCR repertoire of each individual (Fig. 3D). Analysis of paired
2 samples that were sequenced at both d0 and d7 demonstrated that TCR β clonotypes were
3 recalled from the d0 memory CD4⁺ T cell pool into the cTfh cell response at d7 in 10 out of
4 15 individuals (Fig. 3E, F). Recalled TCR β clones represented a median of 25% of the
5 overall TCR repertoire at d7 (Fig. 3G), and were more likely to have been more abundant at
6 d0 compared to clones only detected at d0 (Fig. 3H). Next, we sought to compare pre- and
7 post-vaccination TCR repertoires between individuals. Identical TCR β sequences between 2
8 or more individuals, or ‘public clonotypes’, were present in 18 out 20 cTfh Tet⁺ samples at
9 d7, and represented a median of 10% of the total response (total of 32 distinct public TCR
10 sequences, Fig. 3I-J). In contrast, only 4 public clonotypes were shared across 7 individuals
11 at d0. There was a tendency for public clonotypes to preferentially use particular *TCR β* and
12 *TCR β* gene combinations (Fig. 3K). These results demonstrate that the vaccine-induced
13 cTfh response to A.Cali09 involves reactivation of existing memory CD4⁺ T cells, and that
14 common responses between individuals are a prevalent part of the cTfh cell response.

15

16 **Vaccination-induced cTfh cells share a common transcriptional signature with lymph** 17 **node Tfh cells.**

18 We sought to determine the transcriptional profile of HA-specific cTfh (Tet⁺) cells, and to
19 determine to what extent these cTfh Tet⁺ cells acquired the transcriptional signature of *bona*
20 *fide* human lymph node germinal centre Tfh cells. HA-specific cTfh cells that form seven
21 days after vaccination clustered distinctly from and their d0 Tet⁺ precursors cells by principal
22 component analysis (PC1) for both cohorts (Fig. 4A). 684 genes were differentially expressed
23 in Tet⁺ cTfh cells compared to d0 Tet⁺ cells across both cohorts (DESeq2 Log₂FC > 0.5, FDR
24 p-value <0.1, Data File S1). This gene signature was compared to a 1179 gene signature
25 generated by comparing germinal centre Tfh cells (CXCR5⁺PD1⁺⁺⁺) to non-Tfh antigen-
26 experienced CD4⁺ T cells from human inguinal lymph node (20) (Data File S2). 147 of the
27 differentially expressed genes in Tet⁺ cTfh cells shared the same expression pattern with
28 genes up or downregulated in germinal centre Tfh signature, termed “Tfh genes”, and
29 included upregulation of key Tfh transcription factors *MAF* and *TOX2*, and downregulation
30 of several cytokine and chemokine receptors such as *IL7R*, *IL2RA*, and *CCR6* (Fig. 4B, C,
31 Data File S3). The remaining 537 genes, termed ‘Vaccination genes’, were modulated after
32 influenza vaccination but not differentially expressed in our human lymph node Tfh cell
33 samples. This list included the downregulation of *CXCR4*, a chemokine receptor that is

1 important for lymph node homing consistent with the blood localisation of the cTfh cells
2 (26), and upregulation of the interferon-gamma inducible gene *GBP2*. This gene-level
3 analysis indicated that Tet⁺ cTfh cells share features of a transcriptional profile with lymph
4 node Tfh cells, while also expressing genes specific either to the Th1-skewed response to
5 influenza vaccination or to circulation in the blood.

6
7 To gain a clearer understanding of what molecular pathways were modulated during the
8 differentiation into Tfh cells after vaccination at a transcriptional level, we performed gene
9 set enrichment analysis using the Hallmarks gene sets (Fig. 4D)(27). Ten gene sets were
10 differentially modulated in d7 Tet⁺ Tfh cells compared to d0 in both cohorts, 8 (80%) of
11 which were also enriched in lymph node germinal centre Tfh cells (Fig. 4D). These ‘Tfh
12 genesets’ included the downregulation several cytokine pathways including IL-2 signalling, a
13 cytokine known to inhibit Tfh differentiation (28, 29), and the upregulation of oxidative
14 phosphorylation, a metabolic process known to be elevated in Tfh cells (Fig. 4E) (30, 31).
15 Enrichment for the interferon alpha response and reactive oxygen species pathways were not
16 shared with lymph node Tfh cells, and may reflect the acute response to inactivated virus in
17 the vaccine to which the lymph node Tfh cells were not exposed. Overall, our analysis
18 demonstrates that seasonal influenza vaccination recalls antigen-specific memory CD4⁺ T
19 cells and promotes their differentiation into Tfh cells with similarity to lymph node GC Tfh
20 cells.

21
22 **Impaired anti-HA IgG responses in older individuals correlates with failure to fully**
23 **acquire the immune trajectory of younger individuals.**

24 We defined the correlates of influenza vaccine antibody responses in 18-36 year olds to be
25 serum concentrations of BAFF and BCMA, and the frequency of both polyclonal and HA-
26 specific cTfh cells. Next we wanted to investigate how the immune response to seasonal
27 influenza vaccination was impacted in older individuals, a group where the influenza vaccine
28 is less efficacious (32, 33). We compared our cohorts of 18-36 year olds with that of
29 individuals over 65 years old in the same vaccination years (Fig. 5A, cohort 1 median 69
30 years old, cohort 2 median 73.43 years old), and observed that older individuals showed
31 lower HA-specific IgG responses compared to 18-36 year olds for all the vaccine strains
32 measured (Fig. 5B). To investigate whether ageing broadly influenced immune status pre-
33 and post-vaccination, we applied a diffusion pseudotime algorithm to 23 antibody, cytokine
34 or immunophenotyping variables measured at d0 and d7 for both age-groups and cohorts

1 (Table S1). The immune profiles formed a single continuous spectrum, with the pseudotime
2 ‘vaccination trajectory’ beginning with d0 samples and ending with d7 samples from
3 18-36 year old samples (Fig. 5C). There was no pre-vaccination difference in trajectory
4 values between the age-groups, indicating that ageing did not impact the baseline status for
5 the immune parameters involved in the vaccination response (Fig. 5D). In contrast, over 65
6 year olds failed to progress along the vaccination trajectory to the same extent as their 18-36
7 year olds counterparts (Fig. 5D), indicating a failure to appropriately respond to vaccination.
8 11 immune parameters correlated with the vaccination trajectory values, including antibody
9 responses to the vaccination strains, cTfh cells, HA-specific T cells and diminished serum
10 BAFF (Fig. 5E). These results indicate that in over 65 year olds there is a failure to fully
11 engage the adaptive immune system in response to vaccination compared to younger
12 individuals.

13
14 In order to identify which immune parameters may explain the age-related difference in
15 vaccination trajectory, we compared the 53 immune parameters between age-groups before
16 and after vaccination. Older individuals had higher titres of IgG to several HA proteins from
17 different influenza A strains at d0, however no difference was seen in IgG or HAI titre levels
18 for the influenza strains in the vaccines administered to our cohorts (Fig. 5F) suggesting that
19 age-dependent differences in pre-existing antibodies to the vaccine strain does not account
20 for the diminished response. After immunisation, over 65 year olds showed lower vaccine
21 induced IgG responses for numerous HA strains, consistent with the lower IgG responses to
22 the vaccination strains and diminished generation of cross-reactive IgG to other influenza
23 strains (Fig. 5F). For serum cytokines, we observed consistently lower baseline April and
24 TWEAK concentrations, and higher d42 SCF levels in over 65 year olds across both cohorts
25 (Fig. 5G, S7), but there was no age-dependent difference in BAFF or BCMA. No age-related
26 differences in circulating B cell populations were observed pre- or post-vaccination, and no
27 consistent differences were seen for CD4⁺ T cell subsets pre-vaccination, including for the
28 frequency of d0 HA-specific CD4⁺ cells (Fig. 5H, S7). At d7, the frequency of polyclonal
29 cTfh cells and HA-specific Tet⁺ cTfh cells were the only CD4⁺ T cell subsets consistently
30 reduced in older individuals across both cohorts, with the strongest effect on antigen-specific
31 cTfh cells (Fig. 5H-J). There was no consistent difference in the total d7 Tet⁺ HA-specific T
32 cell population with age for both cohorts (Fig. 5H, S7), which suggests that the poor vaccine
33 antibody responses in older individuals is impacted by impaired cTfh cell differentiation (Fig.
34 5J) rather than size of the vaccine-specific T cell pool.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

TCR repertoire diversity in HA-specific cTfh cells is comparable in younger and older individuals.

Poor T cell responses to vaccination have been previously attributed to a contraction of the naïve CD4⁺ T cell population and restriction of the TCR repertoire with age (16, 17), although most human studies have examined the whole repertoire, rather than focusing on vaccine-specific T cells. Our ability to track vaccine specific CD4⁺ T cells enables direct assessment of the repertoire of responding cells, and therefore we sought to determine whether there were ageing-related differences in the clonal diversity of pre or post vaccination of HA-specific CD4⁺ T cells (Fig. 6A). The pre-vaccination diversity is important as our data from young donors demonstrates that a large contribution to the d7 response originates from memory CD4⁺ T cells present prior to vaccination. In pre-vaccination HA-specific Tet⁺ cells there was a slight reduction in TCR diversity in over 65 year olds compared to younger people, although this was only statistically significant in one cohort (Fig. 6B). However, after vaccination no difference was seen in the TCR diversity of the resulting d7 Tet⁺cTfh population between age groups (Fig. 6B), despite the diminished frequency of this population in older individuals. Likewise, no age-related difference in TCR diversity was observed for the total pool of vaccine-specific Tet⁺ population at day 7 (Fig. 6C). As we had observed in younger donors, TCRβ clones were present in both the d0 Tet⁺ and d7 Tet⁺ cTfh populations. There was a trend towards a lower absolute number of recalled clones in older individuals (Fig. 6D), in line with the lower numbers of d7 sequenced cells due to the reduced cTfh population frequency (Fig. S6). However, the proportion of the d7 population that consisted of recalled clones was not impacted by age (Fig. 6E), indicative of equivalent contribution from pre-existing memory cells into the resulting cTfh population between younger and older donors. The affinity of TCR for antigen shapes Tfh differentiation and Tfh vs. Th1 cell fate after influenza vaccination (34-36), and therefore we sought to determine if the age-related decline in Tet⁺ cTfh differentiation could be explained by an age-dependent skew in the TCR repertoire away from Tfh differentiation. We examined the TCRβ clones that were present in both the d7 Tet⁺ and d7 Tet⁺ cTfh populations, and observed strong correlations between clone frequency between the two populations irrespective of age-groups, suggesting that there was no restriction in the TCR repertoire able to give rise to Tfh cells to the HA peptides studied here (Fig. 6F). Together, our data indicate that TCR diversity is not a limiting factor for the Tfh cell response to seasonal influenza

1 vaccination in older individuals, and suggests that the age-associated reduction in cTfh cell
2 frequency is due to other cell-intrinsic or environmental effects on Tfh cell differentiation or
3 survival.

4
5 **HA-specific cTfh cells from older individuals fail to induce Tfh transcriptional**
6 **signatures and display aberrant inflammatory signatures.**

7 We investigated the transcriptome of HA-specific cTfh cells from older individuals to
8 determine if we could identify pathways that could explain the poor Tfh cell differentiation in
9 ageing. With supervised principal component analysis using the 684 genes that are
10 differentially expressed in 18-36 year olds d7 cTfh cells compared to d0, we observed that d7
11 cTfh cells from over 65 year olds were clustered between d0 and d7 samples from younger
12 donors for PC1 in both cohorts (Fig. 6G). Indeed, of the 425 genes that were consistently DE
13 between HA-specific cells from d0 and d7 in older donors from both cohorts, only 170 (40%)
14 were part of the younger d7 signature (Data file S5). Importantly, we did not observe any
15 consistent age-related gene expression differences in pre-vaccination d0 cells, indicating that
16 ageing is not associated with transcriptional changes in resting HA-specific memory cells.
17 These data indicate that cTfh cells from older individuals failed to acquire the full gene
18 signature seen in Tfh cells from younger people.

19
20 To further resolve these age-related transcriptional differences, we performed enrichment
21 analysis with the Hallmarks genesets and observed 7 gene sets that were consistently
22 positively enriched in d7 HA-specific Tet⁺cTfh cells from over 65 year old compared to 18-
23 36 year old individuals (Fig. 6H). Four of these elevated genesets (TNF α signalling via
24 NF κ B; IL2 STAT5 signalling; Apoptosis; Hypoxia) we previously identified as negatively
25 enriched in Tet⁺cTfh from 18-36 year old individuals compared to d0 Tet⁺ cells. This
26 indicates that these genes are normally downregulated as HA-specific CD4⁺ T cells
27 differentiate into Tfh cells in response to vaccination, and that this process appears
28 dysregulated in older individuals. The remaining three enriched genesets (Interferon gamma
29 response; Inflammatory response; Complement) are suggestive of heightened pro-
30 inflammatory responses in cTfh cells from older individuals, and included enrichment for
31 *IL6*, *CCL2* and *CCL5*. No pathways were altered by ageing in pre-vaccination d0 Tet⁺ cells,
32 indicating that the enrichment for numerous inflammatory pathways in Tfh cells from older
33 people occurred as part of the response to vaccination, rather than being a generalisable
34 feature of CD4⁺ biology in ageing. To further investigate the upregulation of inflammation

1 and cytokine signalling in cTfh cells from older donors, we used the leading-edge output
2 from the gene set enrichment results to curate 3 non-overlapping gene lists of ‘TNF’, ‘IL2’
3 and ‘Inflammation’ (Table S2). We then calculated 3 gene list scores by generating gene z-
4 scores for each cohort, and then summing the z-scores for the genes in each of the gene lists
5 for each sample, before and after vaccination. For all three gene signatures, while there was
6 no pre-vaccination difference between the age-groups, d7 cTfh cells from older donors failed
7 to downregulate the expression of these genes to the same extent as cTfh cells from 18-
8 36 year olds (Fig. 6I). In summary, our transcriptional analysis indicated that in older
9 individuals, cTfh cells display evidence of inflammatory cytokine signalling that is not
10 typical of Tfh cells in younger people.

11

12 **Vaccine induced transcriptional signatures of inflammation, TNF and IL-2 signalling** 13 **negatively correlate with Tfh differentiation and antibody responses.**

14 We sought to determine whether the down-regulation of the inflammatory, IL-2 and TNF
15 pathways in Tet⁺cTfh cells was linked to Tfh cell differentiation and antibody responses after
16 vaccination. Irrespective of age, the three gene scores were negatively correlated with the
17 Tet⁺ cTfh cell frequency (Fig. 7A), and the vaccine-induced A.Cali09 IgG response (Fig. 7B).
18 Our findings suggest that the presence of pro-inflammatory cytokine signalling in cTfh cells
19 induced by vaccination negatively impacts optimal vaccine responses. In order to determine
20 whether the observed negative correlation between the three inflammatory gene signatures
21 and IgG response to seasonal influenza vaccination could be replicated in other cohorts, we
22 analysed PBMC microarray data and A.Cali09 anti-HA antibodies from an independent
23 cohort of 50 adults aged 18-86 year olds from the U.S.A (8). Consistent with our cohorts, we
24 did not detect any age-related difference in gene signatures present prior to vaccination, but
25 the gene signatures induced by vaccination d7 (relative to d0) in PBMCs were negatively
26 correlated with IgG production at d28 (Fig. 7C). This demonstrated that expression of genes
27 associated with inflammation, TNF, and IL-2 signalling in blood is negatively associated
28 with impaired IgG responses to seasonal influenza vaccination, irrespective of age. These
29 data suggest that generation of a high-titre antibody response to vaccination requires the
30 cytokine milieu in secondary lymphoid tissues to be carefully controlled to limit persistent
31 pro-inflammatory cytokine signalling during Tfh differentiation.

32

33 **Discussion:**

1 The formation of virus neutralising antibodies after influenza vaccination provides
2 protections against subsequent infection, yet the cellular and molecular pathways that support
3 a high-titre antibody response in humans remain incompletely defined. Here a systems
4 immunology approach was used to determine which immune parameters are associated with
5 antibody formation upon vaccination. We used MHC class II tetramers to track the formation
6 and differentiation of haemagglutinin-specific CD4⁺ T cells after vaccination, ensuring the
7 specificity of the CD4⁺ T cell response can be accurately matched to the A.Cali09 antibody
8 response. HA-specific cTfh cell frequency was strongly correlated with anti-A.Cali09
9 antibodies six weeks after vaccination, and there was not a reproducible relationship between
10 total HA-specific CD4⁺ T cells and antibody titre, highlighting the importance of
11 antigen-specific Tfh cell differentiation to support humoral immunity. TCR repertoire
12 analysis showed that HA-specific cTfh cells formed from pre-existing memory cells in both
13 younger and older adults, but their differentiation was reduced in older people. Interestingly,
14 there was no difference in TCR repertoire diversity in cTfh cells in ageing, indicating that a
15 contraction of the TCR repertoire with ageing is unlikely to be the cause of poor Tfh cell
16 differentiation in older people. The defective cTfh response in ageing was, however,
17 associated with an enhanced pro-inflammatory gene expression signature, suggesting that
18 excess inflammation can limit the response to vaccination. We were able to confirm that
19 these enhanced inflammatory signatures associated with poor antibody titre in an independent
20 cohort of influenza vaccinees. Together, this suggests that formation of antigen-specific Tfh
21 cells is essential for high titre antibody responses, and that excessive T cell-extrinsic
22 inflammatory factors contribute to poor cTfh cell and antibody responses to vaccination.

23

24 In order to understand what type of immune response supports protective antibody
25 production upon vaccination we comprehensively analysed the immune response to seasonal
26 influenza vaccination by measuring IgG responses to 32 HA proteins, 8 cytokines and
27 chemokines, B cells, CD4⁺ T cells and HA-specific CD4⁺ T cells. This combined approach
28 enabled us to identify which parameters were correlated with the antibody response after
29 vaccination. In contrast to previous studies (22, 37), we observed that the frequencies of
30 circulating B cell populations including plasmablasts did not correlate with the long-term
31 antibody response. This suggests that the circulating plasmablasts observed seven days after
32 vaccination in people are likely biomarkers of the early extrafollicular antibody response that
33 provides a short initial burst of antibodies, rather than of long-lived plasma cells (38).
34 However, the down-regulation of BAFF and up-regulation of one of its receptors, BCMA, in

1 serum over the first 7 days after vaccination clearly demonstrate that dynamic regulation of B
2 cell responses through BAFF and its receptors are tightly intertwined with the magnitude of
3 the antibody output to vaccination. Consistent with this, the up-regulation of *TNFRSF17*, the
4 gene for BCMA, has been well reported to correlate with vaccine titres in PBMC
5 transcriptomics (8, 39-41). Importantly, we show that expansion of Tfh cells, both polyclonal
6 and HA-specific, were consistently correlated with the magnitude of antibody responses
7 across two cohorts. Through sequencing the HA-specific cells we were able to show that
8 cTfh cells are recalled from the resting memory CD4⁺ T cell compartment, that public TCR
9 clonotypes are readily detectable in antigen-specific cTfh cells, and that antigen-specific cTfh
10 cells share a transcriptional program with lymph node Tfh that includes the downregulation
11 of TNF and IL-2 signalling. As age is one of the key factors that influences antibody
12 responses to vaccines (42-44), by clearly defining ideal immune responses in younger
13 individuals we were able to gain novel insights into how ageing negatively impacts the
14 immune response resulting in low titre antibody responses following seasonal influenza
15 vaccination.

16
17 Impaired T cell responses to vaccines in ageing has been proposed to be caused by
18 contraction of the TCR repertoire and the accumulation of terminally differentiated effector
19 cells. However, in our study, we observed impaired antigen-specific Tfh differentiation in
20 older people, despite no defect in the overall antigen-specific CD4⁺ T cell response. Through
21 analysing the clonal relatedness in the TCR repertoire of HA peptide-specific T cells from
22 before and after vaccination, we observed that similar frequencies of d7 cTfh cell clonotypes
23 were recalled by vaccination from resting memory CD4⁺ T cell compartment in both age
24 groups. This suggests that the ability of memory cells to be recalled by vaccines in ageing is
25 not compromised. Furthermore, we observed no difference in the diversity of the TCR
26 repertoire of the cTfh cells that formed after vaccination between age-groups. Therefore, this
27 suggests that a loss of diversity in the T cell repertoire with age does not explain the impaired
28 Tfh differentiation we observed in our study. Impaired Tfh responses to vaccines have been
29 observed in humans and mice (9, 45), however, interestingly the formation of pre-Tfh cells
30 remains intact but there is a failure to generate bona fide GC Tfh cells (45, 46). Together with
31 our data, this suggests that instead of intrinsic defects in CD4⁺ T cells pre-vaccination in
32 older people, the reduced cTfh cell frequency post vaccination may be explained by extrinsic
33 factors, such as inflammation, that lead to a failure to appropriately acquire the GC Tfh cell
34 gene signature.

1
2 Ageing is often associated with a state of low grade inflammation, termed
3 ‘inflammaging’ (47-49). However, in this study we observed no age-related difference in
4 inflammatory gene signatures in HA-specific CD4⁺ T cells at day 0, which suggests the cTfh
5 cell response was negatively impacted by inflammation post vaccination, rather than pre-
6 existing inflammation having affected resting memory T cell function prior to vaccination.
7 Because older people are more at risk of severe health outcomes after infection, significant
8 effort has been made to alter vaccine formulations to enable them to be effective in this age
9 group. Modifications to vaccines to increase the antibody response in older individuals now
10 include increasing the antigen dose and using more potent adjuvants (50, 51), which enhance
11 the inflammatory response. We have previously demonstrated in older people and aged mice
12 that type 1 interferon and TLR7 signalling is important for conventional dendritic cells type 2
13 to support Tfh differentiation after vaccination (9). These studies, together with the data
14 presented here, prompt the hypothesis that while some types inflammation are ‘good’ for
15 promoting long-lived antibody responses in ageing, cytokines such as TNF and IL-2 are ‘bad’
16 and negatively impact a Tfh-supported response to vaccination. Consistent with this,
17 inhibition of inflammatory monocyte recruitment into the skin of older people enhanced the
18 local CD4 T cell response to varicella zoster virus antigen challenge (52). Therefore,
19 vaccination strategies that support humoral immunity through limiting ‘bad’ pro-
20 inflammatory signalling may be the key to improving vaccine efficacy in older people.

21
22 Our data demonstrates that IL-2 is one signalling pathway that is normally downregulated
23 during Tfh differentiation. IL-2 is a cytokine produced by T cells early after T cell activation
24 that promotes clonal expansion, and favours a Th1 cell fate at the expense of Tfh cell
25 differentiation (28, 31), in line with the negative relationship observed here between cTfh cell
26 differentiation and the response to IL-2 in those cells. Tfh cells are reported to be IL-2
27 producers as a consequence of heightened T cell receptor signalling, and whilst they typically
28 do not respond to IL-2, they provide a source of this cytokine to support non-Tfh cells (29).
29 Transcript levels for *IL2* were not increased in cTfh cells from older donors, however *IL2RB*
30 was increased suggesting that the failure to downregulate an IL-2 gene signature in ageing
31 could be due to increased response to IL-2 in the local environment after vaccination.
32 Alternatively, IL-2 signalling gene signature may reflect a failure to fully acquire the Tfh
33 transcriptional program, which may result from memory T cells receiving inadequate Tfh

1 lineage commitment signals from the local environment, such as dendritic cell priming which
2 is known to be impaired in aged mice (9).
3
4 TNF signalling in cTfh cells was also negatively correlated with Tfh differentiation and
5 antibody response upon vaccination. While this cytokine is necessary for the formation of
6 primary B cell follicles and follicular dendritic cell networks that underpin the formation of
7 germinal centers (53-56), it has also been implicated in the loss of germinal centres and
8 disorganisation of secondary lymphoid organ architecture during infections and
9 immunizations in mice (57, 58). The role for TNF in Tfh cell differentiation or survival
10 remains unclear, and it is noteworthy that this pleiotropic cytokine can regulate many aspects
11 of T cell biology, including NF- κ B signalling, TCR signalling, and apoptosis pathways (59).
12 In our study, this TNF signalling signature did not include the *TNF* gene, nor were *TNF*
13 transcripts altered in cTfh cells with age. While in our study, serum concentrations for both
14 TNF and IL-2 were below the limit of detection in most samples, serum TNF levels and TNF
15 production from memory B cells have been reported to increase with age (60, 61), suggesting
16 our TNF signature in cTfh cells may result from paracrine sources within the lymph node.
17 TNF/TNF-receptor signalling has been linked to reduced memory CD4⁺ T cell frequencies
18 after influenza infection in mice (62, 63), and T cells from older people have been found to
19 be more sensitive to TNF-alpha-induced apoptosis via the extrinsic pathway (64, 65),
20 suggesting TNF may impact Tfh cell expansion or survival. In agreement with this, we
21 observed some gene overlap between the apoptosis and TNF signatures downregulated in
22 young cTfh cells on day 7 relative to day 0, and elevated in cTfh cells in older people. More
23 research is required to understand how TNF may regulate germinal centre biology,
24 particularly as elevated TNF correlated with impaired germinal centres and absence of Tfh
25 cells observed in patients that succumbed to COVID-19 infection (66, 67), and has been
26 negatively correlated with Tfh cell frequency in symptomatic SARS-COV2 infected patients
27 (68). Therefore, while it is unclear whether TNF acts directly on T cells to impair Tfh
28 differentiation or survival, or has a broader effect on lymphoid organ architecture, our data
29 indicates that persistence of TNF signalling in cTfh cells is linked to poor vaccine responses.
30
31 The need to develop effective vaccines that are effective in all age groups has been
32 emphasised by the COVID19 pandemic, in which older people are more likely to become
33 seriously ill, or die, after infection(69). Promisingly, multiple SARS-CoV2 vaccines are able
34 to induce strong antibody responses in older people. While a single dose of adenoviral

1 vectored vaccines results in a lower antibody titre in older people, this can be boosted to
2 comparable levels to younger adults with a second dose (70, 71). Mechanistic studies in mice
3 show that this is due to the second vaccine dose enhancing Tfh cells and the germinal center
4 response to a greater extent in aged mice than in younger adult animals (72). COVID19
5 mRNA vaccines induce high titre antibodies after two doses in all age groups (73-75), and
6 generate superior germinal center responses than protein subunit vaccines in young mice (76)
7 and humans (pre-printed in (77)). Together with the data presented here, this demonstrates
8 that effective vaccines are ones that promote the germinal centre response. Therefore
9 vaccination strategies that induce the optimal inflammatory environment to support Tfh
10 differentiation is key to generating enduring antibody mediated immunity.

11

12 **Materials and Methods:**

13 ***Human Cohorts***

14 Peripheral blood was collected from healthy UK adults recruited through the NIHR
15 Bioresource and vaccinated with the trivalent influenza vaccine. Participants were selected on
16 the basis of having at least one allele of either *HLADR*0701* or *HLADR*1101* as determined
17 by single nucleotide polymorphism typing using the UKBiobank v2.1 Axiom array. Two
18 cohorts were collected: Cohort 1, northern hemisphere winter 2014-15, n=16 participants 18-
19 36 years old, n=18 participants 66-75 years old; Cohort 2, northern hemisphere winter 2016-
20 17, n=21 participants 18-36 years old, n=21 participants 66-98 years old. Venous blood was
21 collected for serum and into EDTA coated tubes for peripheral blood mononuclear cell
22 (PBMC) processing on the day of vaccination (prior to administration of the vaccine), 7 and
23 42 days after vaccination. PBMC were isolated by density gradient separation using
24 Histopaque-1077 (Sigma), frozen in Foetal Bovine Serum supplemented with 10% Dimethyl
25 sulfoxide (Sigma) and kept in liquid nitrogen prior to analysis by flow cytometry or flow
26 sorting for RNA sequencing. Lymph node samples were taken from patients recruited from
27 the renal transplant live donor program at Cambridge University Hospitals NHS Foundation
28 Trust, as part of the routine operative procedure, as described previously (20, 78).

29

30 ***Ethics***

31 All human blood and tissue were collected in accordance with the latest revision of the
32 Declaration of Helsinki and the Guidelines for Good Clinical Practice (ICH-GCP). The
33 seasonal UK influenza vaccination cohort was collected with UK local research ethics

1 committee approval (REC reference 14/SC/1077), using the facilities of the Cambridge
2 Bioresource (REC reference 04/Q0108/44). Lymph node samples were collected from UK
3 adults undergoing surgery for their own medical care, under ethical approval from UK Health
4 Research Authority (REC reference 11/EE/0355, respectively), at Cambridge University
5 Hospitals, and processed at the Babraham Institute. Written informed consent was received
6 from all volunteers.

7 8 ***Flu HA and cytokine Luminex***

9 IgG to influenza HA proteins was measured before and after vaccination by Luminex using
10 magnetic beads coated with full length recombinant haemagglutinin proteins, as previously
11 reported (79). Proteins were expressed using baculovirus expression system in insect cells and
12 coupled to Bio-plex Pro Magnetic COOH Beads (Bio-Rad, Hercules, CA). Titres are
13 represented as arbitrary units per mL, calculated from a total IgG standard curve. The lower
14 limit of detection for each HA protein was defined as the mean+ 2 standard deviations
15 measured for the HA-coated beads with secondary antibody only. Where indicated, pre-
16 existing IgG titres were subtracted to from day 7 and 42 titres to calculate vaccination-induced
17 IgG responses. Serum samples were analysed for cytokine and chemokine concentrations using
18 Human Magnetic Luminex kit (Cat# LXSAHM, R&D systems) custom ordered to detect the
19 following analytes: BAFF, CXCL13, BCMA, APRIL, TWEAK, Osteopontin, SCF, Light.
20 Analytes were included for further analysis if more than 50 percent of samples had values
21 above the lower limit of detection.

22 23 ***Hemagglutination inhibition assay***

24 Antibody titers pre and post vaccination were determined using the hemagglutination
25 inhibition (HAI) assay using the standard WHO protocol, as previously described (80). Sera
26 were treated overnight with receptor-destroying enzyme (Denka Seiken Co.) and were
27 subsequently tested by standard methods using 4 HA units of virus and a 0.5% suspension of
28 turkey red blood cells. HAI titers were recorded as the reciprocal of the highest dilution of the
29 serum that completely inhibited agglutination of erythrocytes by 4 HA units of the virus.

30 31 ***Flow cytometry of B cells and FACS sorting of T lymphocytes***

32 Cryopreserved mononuclear cells were thawed and rested for 1 hour at 37°C. Fc receptors
33 were blocked using anti-human CD32 antibody (clone 6C4, eBioscience). 4 million PBMCs

1 were stained with a panel of antibodies to measure B cells (Table S2), acquired on BD LSR
2 Fortessa5 cytometer, and gated according to the strategy outlined in Fig. S1. For T cell
3 staining and sorting, between 15-40 million PBMCs were first treated with 50nM dasatinib
4 (Sigma) for 10minutes at 37°C, and then stained with PE-conjugated tetramers for 2 hours at
5 room temperature with methods and reagents that have been previously reported (15)
6 (Benaroya Research Institute Tetramer core facility). Tetramers were loaded with peptides of
7 hemagglutinin (HA) protein specific to the A/California/04/2009(H1N1) influenza strain
8 (GenBank: ACQ76318.1), with the HLADR*0701 tetramer containing the peptide
9 ITFEATGNLVVPRYAFAMER which corresponds to amino acids 257-276, and
10 HLADR*1101 tetramer contained the peptide FYKNLIWLKKGNSYPKLSK which
11 corresponds to amino acids 161-180(15). Tetramer stained PBMCs were then enriched for
12 memory CD4⁺ T cells using by magnetic separation (MagniSort enrichment, eBioscience),
13 and subsequently stained with the antibody panel outlined in Table S3. HA-specific T cells
14 were isolated using a FACSAria™ Fusion Sorter (BD Biosciences) by first excluding
15 unwanted cell types using a dump channel consisting of viability dye and antibodies to CD14,
16 CD16, and CD19. CD3+CD4+CD45RA⁻ tetramer binding cells were sorted and further
17 phenotyping was performed using the gating strategy outlined in Fig. S2. Up to 1000 HA-
18 specific tetramer+ cells were sorted directly into 9µL of lysis buffer containing RNase
19 inhibitor as per the SMART-Seq® v4 Ultra® Low Input RNA Kit for Sequencing manual
20 (Takara), with the additional markers CXCR5 and PD1 used to isolate tetramer binding cTfh
21 cells in d7 samples. Additional CD4⁺ T cell subsets were analysed post acquisition as per the
22 gating strategy outlined in Fig. S3.

23

24 ***RNA sequencing and data processing***

25 mRNA was converted to cDNA using the SMART-Seq v4 Ultra Low Input RNA Kit (Takara
26 Bio). Sequencing libraries were subsequently generated using the Nextera XT DNA Library
27 Prep Kit (Illumina), followed by sequencing on the Illumina HiSeq 2000 with ~50 million
28 100-bp single-end reads per sample. mRNA from lymph node CD4⁺CD45RA⁻ T cell
29 populations was isolated from 1000 cells sorted into lysis buffer from 6 individuals as
30 previously described (20). Sequencing reads were aligned to the reference human genome
31 GRCh38 using HISAT2 (81), and quantitated using Rsubread package (82). Samples were
32 excluded on the basis of poor cDNA quality prior to sequencing, or where drop-out genes
33 with zero counts represented more than 80% of total reads. Genes were filtered based on

1 having more than 10 reads in 20% of samples, yielding 19113 genes. Unwanted variation due
2 to batch effects and sex was determined using the RUVseq package (83) for each cohort
3 separately using the model.matrix [~data\$sex +data\$group], where the 'group' factor
4 represents the combination of time-point, cell type and age-group. The RUVseq output was
5 incorporated into DESeq2 model matrix design using the following model [design = ~ W_1 +
6 W_2 + W_3 + sex + group] where W represents the three RUVseq variance factors identified
7 for each cohort. DESeq2 fold changes were adjusted using the lfcShrink normal method, and
8 variance stabilised normalisation was applied to the counts to give an expression value per
9 gene (DESeq2 package (84, 85)). Significantly differentially expressed genes had adjusted p-
10 values of <0.1 and log2fold change of 0.5 or greater, with consistent changes across both
11 cohorts or comparisons. Pathway analysis was performed using the Hallmark genesets
12 (MSigDB collections (27)) on gene lists ranked by log2Fold change using the fgsea R
13 package (86). Significantly enriched pathways had adjusted p-values of <0.1 and normalised
14 enrichment scores of <-1 or >1, consistently across both cohorts or comparisons. The lymph
15 node germinal centre Tfh signature was generated by comparing Tfh with
16 CD4+CD45RA-CXCR5- and CD4+CD45RA-CXCR5+PD1- non-Tfh cell populations.
17 Genes were selected on the basis of a DESeq2 adjusted P-value cutoff <0.1 and log2 fold
18 change of greater of less than 0.5, for both non-Tfh populations. Pathways analysis using the
19 fgsea package was used to define enriched pathways as described above.

20
21 Signature genes were determined from the fgsea defined leading-edge gene lists for TNF
22 signalling pathway, IL-2 STAT5 signalling pathway, and inflammation pathways (Interferon
23 gamma, Inflammatory response, and Complement combined). Genes present in the leading-
24 edge for both cohorts were included, and where a gene was present across multiple pathways,
25 it was assigned to the pathway where it was ranked highest, ensuring each gene signature was
26 non-overlapping. VSN normalised gene expression values for selected signatures were then
27 converted to z-scores with all time-points combined, and then z-scores were summed for each
28 sample (87). Microarray data of PBMCs from GSE74813 (8, 88) were re-analysed as follows:
29 Raw. CEL files were downloaded from GEO with the corresponding annotation data. CEL
30 files were read into R via Affy package(89) and were normalised using VSN (84). The
31 dataset was then filtered to select only individuals with paired day 0 and day 7 samples. Gene
32 z-scores were then calculated and summed across gene signatures for each sample as

1 described above, with the summed gene signature scores for d0 subtracted from d7 scores for
2 each sample for correlation to antibody titres, which were made available upon request (8).

3

4 ***T cell receptor sequencing and clonotype analysis:***

5 TCR β clonotypes were called from adaptor-trimmed RNA sequencing fastq files using
6 MIXCR (version 2.1.9;(90)) run in RNA-Seqmode with rescuing of partial alignments and
7 set to collate *TCRA* or *TCRB* clonotypes at the amino acid level and requiring more than five
8 reads to identify a clonotype. Clonotype diversity was determined using vjtools (version
9 1.0.3; (91)). Recalled *TCRB* clones were determined by analysing paired d0 and d7 samples
10 from the same individual for both cohorts combined, and clonotype defined by CDR3 amino
11 acid sequence, V, D and J gene usage. Public *TCRB* clonotypes were analysed for both
12 cohorts combined, and each time-point separately, with V and J gene usage among public
13 clones compared for each time-point and genotype separately.

14

15 ***Vaccination trajectory and pseudotime analysis***

16 The trajectory analysis was assembled as previously described (7, 92). Briefly, the
17 frequencies for immune parameters were first normalized for abundance by subtracting the
18 mean and dividing by the standard deviation for both cohorts combined. Variables with
19 missing values were excluded, leaving 35 variables analysed for each time-point (Table S1)
20 Principal components analysis was then performed, in which the samples from different time-
21 points showed separated by PC1. Therefore, the immune parameters that had a correlation to
22 PC1 greater than 0.4 were included ($n = 23$ cell types). The diffusion maps algorithm was
23 then applied to the scaled frequencies using the destiny R package(93, 94), the resulting
24 diffusion pseudotime values (described as vaccination trajectory) were scaled to a range of 0
25 to 1 and compared between time-points and age-groups. Correlations between vaccination
26 trajectory and cell type frequencies were analysed by Spearman's correlation.

27

28 ***Statistics***

29 All statistical tests for cell type frequencies assumed nonparametric data. Fold change for
30 immune parameters was calculated by dividing d7 or d42 frequency by d0, and post
31 vaccination increases relative to baseline were determined by subtracting d0 from d7 or d42
32 data. Two-group comparisons were made using either two-tailed Mann-Whitney tests or
33 Wilcoxon tests for paired data from the same individual at different time points. Multiple

1 group comparisons p-values were calculated using Dunn’s post hoc test. Correlation analyses
2 used Spearman correlation, with the exception of log normalised TCRB clone frequency
3 analysis which used Pearson correlation. As necessary, FDR (Benjamini-Hochberg)
4 adjustment was used to adjust for multiple testing on two-group comparisons. Heatmaps of
5 manual gated cell subsets that were altered by vaccination or age group were generated using
6 Pheatmap package (95).

8 **Acknowledgements**

9 The NIHR Cambridge Biomedical Research Center (BRC) is a partnership between
10 Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge,
11 funded by the National Institute for Health Research (NIHR). We are indebted to the NIHR
12 Cambridge BRC volunteers for their participation and we thank the NIHR Cambridge BRC
13 staff for their contribution in co-ordinating the vaccinations and venepuncture. We thank the
14 staff of the Babraham Institute Flow Cytometry Facility and the Sequencing Facility for their
15 technical assistance. We are grateful to the Babraham Bioinformatics Group for their help.
16 This study was supported by H2020 European Research Council funding awarded to MAL
17 (637801-TWILIGHT) and the Biotechnology and Biological Sciences Research Council
18 (BBS/E/B/000C0427, BBS/E/B/000C0428, and the Campus Capability Core Grant to the
19 Babraham Institute). DLH is supported by a National Health and Medical Research Council
20 Australia Early-Career Fellowship (APP1139911). JCL is supported by a Wellcome Trust
21 Intermediate Clinical Fellowship (105920/Z/14/Z). MAL is an EMBO Young Investigator
22 and Lister Institute Prize Fellow. This paper presents independent research supported by the
23 NIHR Cambridge BRC. The views expressed are those of the authors and not necessarily
24 those of the NIHR or the Department of Health and Social Care.

26 **Author contributions**

27 Conceptualization, M.A.L., E.J.C and D.L.H; Methodology, D.L.H, E.J.C., S.I., J.W., M.Z.,
28 E.A.J., W.W.K and M.A.L; Investigation, D.L.H, E.J.C., S.I., J.W., M.Z., and M.A.L;
29 Clinical Leads, J.C.L and E.J.C. Writing – Original Draft Preparation, D.L.H., and M.A.L.;
30 Writing – Review and Editing, all authors; Project Administration, M.A.L., D.L.H and E.J.C;
31 Funding Acquisition, M.A.L.

33 **Declaration of Interests**

1 The authors declare no competing interests. The funders played no role in the
2 conceptualization, design, data collection, analysis, decision to publish, or preparation of the
3 manuscript.

4 5 **Supp Figures:**

- 6 Figure S1: B cell flow cytometry gating strategy
- 7 Figure S2: CD4⁺ T cell flow cytometry gating strategy
- 8 Figure S3: HA-specific CD4⁺ T cell sorting strategy
- 9 Figure S4: Cytokine and CD4⁺ T cell variables altered after vaccination
- 10 Figure S5: CXCR3 and CCR6 expression on HA-specific CD4⁺ T cells
- 11 Figure S6: Cell number and clonotype number from T cell sequencing
- 12 Figure S7: Age-related differences in cytokines and HA-specific CD4⁺ T cell parameters
- 13 Table S1: Immunological variables
- 14 Table S2: Inflammation, TNF and IL-2 gene signatures
- 15 Table S3: Antibody panel for B cells
- 16 Table S4: Antibody panel for T cells
- 17 Data File S1: 18-36 year old samples d7 cTfh vs d0 gene list
- 18 Data File S2: Lymph Node Germinal center Tfh gene signature
- 19 Data File S3: d7 Tfh gene set
- 20 Data File S4: d7 Vaccination genes
- 21 Data File S5: Ageing d7 cTfh vs d0 gene list

22 23 **References**

- 24 1. A. D. Iuliano, K. M. Roguski, H. H. Chang, D. J. Muscatello, R. Palekar, S. Tempia,
25 C. Cohen, J. M. Gran, D. Schanzer, B. J. Cowling, P. Wu, J. Kyncl, L. W. Ang, M.
26 Park, M. Redlberger-Fritz, H. Yu, L. Espenhain, A. Krishnan, G. Emukule, L. van
27 Asten, S. Pereira da Silva, S. Aungkulanon, U. Buchholz, M. A. Widdowson, J. S.
28 Bresee, N. Global Seasonal Influenza-associated Mortality Collaborator, Estimates of
29 global seasonal influenza-associated respiratory mortality: a modelling study. *Lancet*
30 **391**, 1285-1300 (2018).
- 31 2. D. Hobson, R. L. Curry, A. S. Beare, A. Ward-Gardner, The role of serum
32 haemagglutination-inhibiting antibody in protection against challenge infection with
33 influenza A2 and B viruses. *J Hyg (Lond)* **70**, 767-777 (1972).
- 34 3. P. Brodin, V. Jojic, T. Gao, S. Bhattacharya, C. J. Angel, D. Furman, S. Shen-Orr, C.
35 L. Dekker, G. E. Swan, A. J. Butte, H. T. Maecker, M. M. Davis, Variation in the
36 human immune system is largely driven by non-heritable influences. *Cell* **160**, 37-47
37 (2015).
- 38 4. J. N. Frost, T. K. Tan, M. Abbas, S. K. Wideman, M. Bonadonna, N. U. Stoffel, K.
39 Wray, B. Krostesiner, G. Smits, D. R. Campagna, T. L. Duarte, J. M. Lopes, A. Shah,

- 1 A. E. Armitage, J. Arezes, P. J. Lim, A. E. Prestron, D. Ahern, M. Teh, C. Naylor, M.
2 Salio, U. Gileadi, S. C. Andrews, S. J. Dunachie, M. B. Zimmermann, F. R. M. van
3 der Klis, V. Cerundolo, O. Bannard, S. Draper, A. R. M. Townsend, B. Galy, M. D.
4 Fleming, M. C. Lewis, H. Drakesmith, Hepcidin-Mediated Hypoferremia Disrupts
5 Immune Responses to Vaccination and Infection. *medRxiv*, (2020).
- 6 5. D. Furman, V. Jovic, S. Sharma, S. S. Shen-Orr, C. J. Angel, S. Onengut-Gumuscu, B.
7 A. Kidd, H. T. Maecker, P. Concannon, C. L. Dekker, P. G. Thomas, M. M. Davis,
8 Cytomegalovirus infection enhances the immune response to influenza. *Sci Transl
9 Med* **7**, 281ra243 (2015).
- 10 6. C. Giefing-Kroll, P. Berger, G. Lepperdinger, B. Grubeck-Loebenstein, How sex and
11 age affect immune responses, susceptibility to infections, and response to vaccination.
12 *Aging Cell* **14**, 309-321 (2015).
- 13 7. D. L. Hill, E. J. Carr, T. Rutishauser, G. Moncunill, J. J. Campo, S. Innocentin, M.
14 Mpina, A. Nhabomba, A. Tumbo, C. Jairoce, H. A. Moll, M. C. van Zelm, C.
15 Dobano, C. Daubenberger, M. A. Linterman, Immune system development varies
16 according to age, location, and anemia in African children. *Sci Transl Med* **12**,
17 (2020).
- 18 8. H. I. Nakaya, T. Hagan, S. S. Duraisingham, E. K. Lee, M. Kwissa, N. Roupheal, D.
19 Frasca, M. Gersten, A. K. Mehta, R. Gaujoux, G. M. Li, S. Gupta, R. Ahmed, M. J.
20 Mulligan, S. Shen-Orr, B. B. Blomberg, S. Subramaniam, B. Pulendran, Systems
21 Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse
22 Populations Reveals Shared Molecular Signatures. *Immunity* **43**, 1186-1198 (2015).
- 23 9. M. Stebegg, A. Bignon, D. L. Hill, A. Silva-Cayetano, C. Krueger, I. Vanderleyden,
24 S. Innocentin, L. Boon, J. Wang, M. S. Zand, J. Dooley, J. Clark, A. Liston, E. Carr,
25 M. A. Linterman, Rejuvenating conventional dendritic cells and T follicular helper
26 cell formation after vaccination. *Elife* **9**, (2020).
- 27 10. C. G. Vinuesa, M. A. Linterman, D. Yu, I. C. MacLennan, Follicular Helper T Cells.
28 *Annu Rev Immunol* **34**, 335-368 (2016).
- 29 11. T. M. Wilkinson, C. K. Li, C. S. Chui, A. K. Huang, M. Perkins, J. C. Liebner, R.
30 Lambkin-Williams, A. Gilbert, J. Oxford, B. Nicholas, K. J. Staples, T. Dong, D. C.
31 Douek, A. J. McMichael, X. N. Xu, Preexisting influenza-specific CD4⁺ T cells
32 correlate with disease protection against influenza challenge in humans. *Nat Med* **18**,
33 274-280 (2012).
- 34 12. J. M. Dan, C. S. Lindestam Arlehamn, D. Weiskopf, R. da Silva Antunes, C.
35 Havenar-Daughton, S. M. Reiss, M. Brigger, M. Bothwell, A. Sette, S. Crotty, A
36 Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal
37 Center T Follicular Helper Cells and Rare Antigen-Specific CD4⁺ T Cells in Blood. *J
38 Immunol* **197**, 983-993 (2016).
- 39 13. C. Havenar-Daughton, S. M. Reiss, D. G. Carnathan, J. E. Wu, K. Kendric, A.
40 Torrents de la Pena, S. P. Kasturi, J. M. Dan, M. Bothwell, R. W. Sanders, B.
41 Pulendran, G. Silvestri, S. Crotty, Cytokine-Independent Detection of Antigen-
42 Specific Germinal Center T Follicular Helper Cells in Immunized Nonhuman
43 Primates Using a Live Cell Activation-Induced Marker Technique. *J Immunol* **197**,
44 994-1002 (2016).
- 45 14. H. Uchtenhagen, C. Rims, G. Blahnik, I. T. Chow, W. W. Kwok, J. H. Buckner, E. A.
46 James, Efficient ex vivo analysis of CD4⁺ T-cell responses using combinatorial HLA
47 class II tetramer staining. *Nat Commun* **7**, 12614 (2016).
- 48 15. J. Yang, E. James, T. J. Gates, J. H. DeLong, R. E. LaFond, U. Malhotra, W. W.
49 Kwok, CD4⁺ T cells recognize unique and conserved 2009 H1N1 influenza

- 1 hemagglutinin epitopes after natural infection and vaccination. *Int Immunol* **25**, 447-
2 457 (2013).
- 3 16. R. J. Looney, M. S. Hasan, D. Coffin, D. Campbell, A. R. Falsey, J. Kolassa, J. M.
4 Agosti, G. N. Abraham, T. G. Evans, Hepatitis B immunization of healthy elderly
5 adults: relationship between naive CD4⁺ T cells and primary immune response and
6 evaluation of GM-CSF as an adjuvant. *J Clin Immunol* **21**, 30-36 (2001).
- 7 17. E. J. Yager, M. Ahmed, K. Lanzer, T. D. Randall, D. L. Woodland, M. A. Blackman,
8 Age-associated decline in T cell repertoire diversity leads to holes in the repertoire
9 and impaired immunity to influenza virus. *J Exp Med* **205**, 711-723 (2008).
- 10 18. E. Brenna, A. N. Davydov, K. Ladell, J. E. McLaren, P. Bonaiuti, M. Metsger, J. D.
11 Ramsden, S. C. Gilbert, T. Lambe, D. A. Price, S. L. Champion, D. M. Chudakov, P.
12 Borrow, A. J. McMichael, CD4(+) T Follicular Helper Cells in Human Tonsils and
13 Blood Are Clonally Convergent but Divergent from Non-Tfh CD4(+) Cells. *Cell Rep*
14 **30**, 137-152 e135 (2020).
- 15 19. A. Heit, F. Schmitz, S. Gerdt, B. Flach, M. S. Moore, J. A. Perkins, H. S. Robins, A.
16 Aderem, P. Spearman, G. D. Tomaras, S. C. De Rosa, M. J. McElrath, Vaccination
17 establishes clonal relatives of germinal center T cells in the blood of humans. *J Exp*
18 *Med* **214**, 2139-2152 (2017).
- 19 20. D. L. Hill, W. Pierson, D. J. Bolland, C. Mkindi, E. J. Carr, J. Wang, S. Houard, S. W.
20 Wingett, R. Audran, E. F. Wallin, S. A. Jongo, K. Kamaka, M. Zand, F. Spertini, C.
21 Daubenberger, A. E. Corcoran, M. A. Linterman, The adjuvant GLA-SE promotes
22 human Tfh cell expansion and emergence of public TCRbeta clonotypes. *J Exp Med*
23 **216**, 1857-1873 (2019).
- 24 21. M. Locci, C. Havenar-Daughton, E. Landais, J. Wu, M. A. Kroenke, C. L. Arlehamn,
25 L. F. Su, R. Cubas, M. M. Davis, A. Sette, E. K. Haddad, A. V. I. P. C. P. I.
26 International, P. Pognard, S. Crotty, Human circulating PD-1+CXCR3-CXCR5+
27 memory Tfh cells are highly functional and correlate with broadly neutralizing HIV
28 antibody responses. *Immunity* **39**, 758-769 (2013).
- 29 22. S. E. Bentebibel, S. Lopez, G. Obermoser, N. Schmitt, C. Mueller, C. Harrod, E.
30 Flano, A. Mejias, R. A. Albrecht, D. Blankenship, H. Xu, V. Pascual, J. Banchereau,
31 A. Garcia-Sastre, A. K. Palucka, O. Ramilo, H. Ueno, Induction of
32 ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza
33 vaccination. *Sci Transl Med* **5**, 176ra132 (2013).
- 34 23. J. S. Tsang, P. L. Schwartzberg, Y. Kotliarov, A. Biancotto, Z. Xie, R. N. Germain, E.
35 Wang, M. J. Olnes, M. Narayanan, H. Golding, S. Moir, H. B. Dickler, S. Perl, F.
36 Cheung, H. C. Baylor, C. H. I. Consortium, Global analyses of human immune
37 variation reveal baseline predictors of postvaccination responses. *Cell* **157**, 499-513
38 (2014).
- 39 24. S. Sasaki, X. S. He, T. H. Holmes, C. L. Dekker, G. W. Kemble, A. M. Arvin, H. B.
40 Greenberg, Influence of prior influenza vaccination on antibody and B-cell responses.
41 *PLoS One* **3**, e2975 (2008).
- 42 25. K. L. Bucasas, L. M. Franco, C. A. Shaw, M. S. Bray, J. M. Wells, D. Nino, N.
43 Arden, J. M. Quarles, R. B. Couch, J. W. Belmont, Early patterns of gene expression
44 correlate with the humoral immune response to influenza vaccination in humans. *J*
45 *Infect Dis* **203**, 921-929 (2011).
- 46 26. T. Okada, V. N. Ngo, E. H. Ekland, R. Forster, M. Lipp, D. R. Littman, J. G. Cyster,
47 Chemokine requirements for B cell entry to lymph nodes and Peyer's patches. *J Exp*
48 *Med* **196**, 65-75 (2002).

- 1 27. A. Liberzon, C. Birger, H. Thorvaldsdottir, M. Ghandi, J. P. Mesirov, P. Tamayo, The
2 Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst* **1**,
3 417-425 (2015).
- 4 28. A. Ballesteros-Tato, B. Leon, B. A. Graf, A. Moquin, P. S. Adams, F. E. Lund, T. D.
5 Randall, Interleukin-2 inhibits germinal center formation by limiting T follicular
6 helper cell differentiation. *Immunity* **36**, 847-856 (2012).
- 7 29. D. DiToro, C. J. Winstead, D. Pham, S. Witte, R. Andargachew, J. R. Singer, C. G.
8 Wilson, C. L. Zindl, R. J. Luther, D. J. Silberger, B. T. Weaver, E. M. Kolawole, R. J.
9 Martinez, H. Turner, R. D. Hatton, J. J. Moon, S. S. Way, B. D. Evavold, C. T.
10 Weaver, Differential IL-2 expression defines developmental fates of follicular versus
11 nonfollicular helper T cells. *Science* **361**, (2018).
- 12 30. L. Dong, Y. He, S. Zhou, Y. Cao, Y. Li, Y. Bi, G. Liu, HIF1alpha-Dependent
13 Metabolic Signals Control the Differentiation of Follicular Helper T Cells. *Cells* **8**,
14 (2019).
- 15 31. J. P. Ray, M. M. Staron, J. A. Shyer, P. C. Ho, H. D. Marshall, S. M. Gray, B. J.
16 Laidlaw, K. Araki, R. Ahmed, S. M. Kaech, J. Craft, The Interleukin-2-mTORc1
17 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1
18 and Follicular B Helper T Cells. *Immunity* **43**, 690-702 (2015).
- 19 32. T. M. Govaert, C. T. Thijs, N. Masurel, M. J. Sprenger, G. J. Dinant, J. A. Knottnerus,
20 The efficacy of influenza vaccination in elderly individuals. A randomized double-
21 blind placebo-controlled trial. *JAMA* **272**, 1661-1665 (1994).
- 22 33. T. O. Jefferson, D. Rivetti, C. Di Pietrantonj, A. Rivetti, V. Demicheli, Vaccines for
23 preventing influenza in healthy adults. *Cochrane Database Syst Rev*, CD001269
24 (2007).
- 25 34. N. J. Tubo, M. K. Jenkins, TCR signal quantity and quality in CD4(+) T cell
26 differentiation. *Trends Immunol* **35**, 591-596 (2014).
- 27 35. Z. A. Knowlden, A. J. Sant, CD4 T cell epitope specificity determines follicular
28 versus non-follicular helper differentiation in the polyclonal response to influenza
29 infection or vaccination. *Sci Rep* **6**, 28287 (2016).
- 30 36. S. Keck, M. Schmalzer, S. Ganter, L. Wyss, S. Oberle, E. S. Huseby, D. Zehn, C. G.
31 King, Antigen affinity and antigen dose exert distinct influences on CD4 T-cell
32 differentiation. *Proc Natl Acad Sci U S A* **111**, 14852-14857 (2014).
- 33 37. G. M. Li, C. Chiu, J. Wrammert, M. McCausland, S. F. Andrews, N. Y. Zheng, J. H.
34 Lee, M. Huang, X. Qu, S. Edupuganti, M. Mulligan, S. R. Das, J. W. Yewdell, A. K.
35 Mehta, P. C. Wilson, R. Ahmed, Pandemic H1N1 influenza vaccine induces a recall
36 response in humans that favors broadly cross-reactive memory B cells. *Proc Natl*
37 *Acad Sci U S A* **109**, 9047-9052 (2012).
- 38 38. I. C. MacLennan, K. M. Toellner, A. F. Cunningham, K. Serre, D. M. Sze, E. Zuniga,
39 M. C. Cook, C. G. Vinuesa, Extrafollicular antibody responses. *Immunol Rev* **194**, 8-
40 18 (2003).
- 41 39. T. D. Querec, R. S. Akondy, E. K. Lee, W. Cao, H. I. Nakaya, D. Teuwen, A. Pirani,
42 K. Gernert, J. Deng, B. Marzolf, K. Kennedy, H. Wu, S. Bennouna, H. Oluoch, J.
43 Miller, R. Z. Vencio, M. Mulligan, A. Aderem, R. Ahmed, B. Pulendran, Systems
44 biology approach predicts immunogenicity of the yellow fever vaccine in humans.
45 *Nat Immunol* **10**, 116-125 (2009).
- 46 40. O. Sobolev, E. Binda, S. O'Farrell, A. Lorenc, J. Pradines, Y. Huang, J. Duffner, R.
47 Schulz, J. Cason, M. Zambon, M. H. Malim, M. Peakman, A. Cope, I. Capila, G. V.
48 Kaundinya, A. C. Hayday, Adjuvanted influenza-H1N1 vaccination reveals lymphoid
49 signatures of age-dependent early responses and of clinical adverse events. *Nat*
50 *Immunol* **17**, 204-213 (2016).

- 1 41. S. Li, N. L. Sullivan, N. Roupheal, T. Yu, S. Banton, M. S. Maddur, M. McCausland,
2 C. Chiu, J. Canniff, S. Dubey, K. Liu, V. Tran, T. Hagan, S. Duraisingham, A.
3 Wieland, A. K. Mehta, J. A. Whitaker, S. Subramaniam, D. P. Jones, A. Sette, K.
4 Vora, A. Weinberg, M. J. Mulligan, H. I. Nakaya, M. Levin, R. Ahmed, B. Pulendran,
5 Metabolic Phenotypes of Response to Vaccination in Humans. *Cell* **169**, 862-877
6 e817 (2017).
- 7 42. H. L. Dugan, C. Henry, P. C. Wilson, Aging and influenza vaccine-induced
8 immunity. *Cell Immunol* **348**, 103998 (2020).
- 9 43. D. Frasca, B. B. Blomberg, Aging induces B cell defects and decreased antibody
10 responses to influenza infection and vaccination. *Immun Ageing* **17**, 37 (2020).
- 11 44. C. E. Gustafson, C. Kim, C. M. Weyand, J. J. Goronzy, Influence of immune aging on
12 vaccine responses. *J Allergy Clin Immunol* **145**, 1309-1321 (2020).
- 13 45. J. S. Lefebvre, A. R. Masters, J. W. Hopkins, L. Haynes, Age-related impairment of
14 humoral response to influenza is associated with changes in antigen specific T
15 follicular helper cell responses. *Sci Rep* **6**, 25051 (2016).
- 16 46. L. M. C. Webb, S. Fra-Bido, S. Innocentin, L. S. Matheson, N. Attaf, A. Bignon, J.
17 Novarino, N. Fazilleau, M. A. Linterman, Ageing promotes early T follicular helper
18 cell differentiation by modulating expression of RBPJ. *Aging Cell* **20**, e13295 (2021).
- 19 47. L. L. Cunha, S. F. Perazzio, J. Azzi, P. Cravedi, L. V. Riella, Remodeling of the
20 Immune Response With Aging: Immunosenescence and Its Potential Impact on
21 COVID-19 Immune Response. *Front Immunol* **11**, 1748 (2020).
- 22 48. B. Pereira, X. N. Xu, A. N. Akbar, Targeting Inflammation and Immunosenescence to
23 Improve Vaccine Responses in the Elderly. *Front Immunol* **11**, 583019 (2020).
- 24 49. J. E. McElhaney, C. P. Verschoor, M. K. Andrew, L. Haynes, G. A. Kuchel, G.
25 Pawelec, The immune response to influenza in older humans: beyond immune
26 senescence. *Immun Ageing* **17**, 10 (2020).
- 27 50. C. A. DiazGranados, A. J. Dunning, M. Kimmel, D. Kirby, J. Treanor, A. Collins, R.
28 Pollak, J. Christoff, J. Earl, V. Landolfi, E. Martin, S. Gurunathan, R. Nathan, D. P.
29 Greenberg, N. G. Tornieporth, M. D. Decker, H. K. Talbot, Efficacy of high-dose
30 versus standard-dose influenza vaccine in older adults. *N Engl J Med* **371**, 635-645
31 (2014).
- 32 51. S. Squarcione, S. Sgricia, L. R. Biasio, E. Perinetti, Comparison of the reactogenicity
33 and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly
34 subjects. *Vaccine* **21**, 1268-1274 (2003).
- 35 52. E. S. Chambers, M. Vukmanovic-Stejic, B. B. Shih, H. Trahair, P. Subramanian, O. P.
36 Devine, J. Glanville, D. Gilroy, M. H. A. Rustin, T. C. Freeman, N. A. Mabbott, A. N.
37 Akbar, Recruitment of inflammatory monocytes by senescent fibroblasts inhibits
38 antigen-specific tissue immunity during human aging. *Nature Aging* **1**, 101-113
39 (2021).
- 40 53. A. V. Tumanov, S. I. Grivennikov, A. A. Kruglov, Y. V. Shebzukhov, E. P. Koroleva,
41 Y. Piao, C. Y. Cui, D. V. Kuprash, S. A. Nedospasov, Cellular source and molecular
42 form of TNF specify its distinct functions in organization of secondary lymphoid
43 organs. *Blood* **116**, 3456-3464 (2010).
- 44 54. M. Pasparakis, L. Alexopoulou, V. Episkopou, G. Kollias, Immune and inflammatory
45 responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the
46 formation of primary B cell follicles, follicular dendritic cell networks and germinal
47 centers, and in the maturation of the humoral immune response. *J Exp Med* **184**,
48 1397-1411 (1996).
- 49 55. M. Pasparakis, S. Kousteni, J. Peschon, G. Kollias, Tumor necrosis factor and the
50 p55TNF receptor are required for optimal development of the marginal sinus and for

- 1 migration of follicular dendritic cell precursors into splenic follicles. *Cell Immunol*
2 **201**, 33-41 (2000).
- 3 56. Y. Wang, J. Wang, Y. Sun, Q. Wu, Y. X. Fu, Complementary effects of TNF and
4 lymphotoxin on the formation of germinal center and follicular dendritic cells. *J*
5 *Immunol* **166**, 330-337 (2001).
- 6 57. V. Ryg-Cornejo, L. J. Ioannidis, A. Ly, C. Y. Chiu, J. Tellier, D. L. Hill, S. P.
7 Preston, M. Pellegrini, D. Yu, S. L. Nutt, A. Kallies, D. S. Hansen, Severe Malaria
8 Infections Impair Germinal Center Responses by Inhibiting T Follicular Helper Cell
9 Differentiation. *Cell Rep* **14**, 68-81 (2016).
- 10 58. M. Popescu, B. Cabrera-Martinez, G. M. Winslow, TNF-alpha Contributes to
11 Lymphoid Tissue Disorganization and Germinal Center B Cell Suppression during
12 Intracellular Bacterial Infection. *J Immunol* **203**, 2415-2424 (2019).
- 13 59. A. K. Mehta, D. T. Gracias, M. Croft, TNF activity and T cells. *Cytokine* **101**, 14-18
14 (2018).
- 15 60. E. J. Carr, J. Dooley, J. E. Garcia-Perez, V. Lagou, J. C. Lee, C. Wouters, I. Meyts, A.
16 Goris, G. Boeckxstaens, M. A. Linterman, A. Liston, The cellular composition of the
17 human immune system is shaped by age and cohabitation. *Nat Immunol* **17**, 461-468
18 (2016).
- 19 61. D. Frasca, A. Diaz, M. Romero, A. M. Landin, B. B. Blomberg, High TNF-alpha
20 levels in resting B cells negatively correlate with their response. *Exp Gerontol* **54**,
21 116-122 (2014).
- 22 62. M. P. DeBerge, K. H. Ely, R. I. Enelow, Soluble, but not transmembrane, TNF-alpha
23 is required during influenza infection to limit the magnitude of immune responses and
24 the extent of immunopathology. *J Immunol* **192**, 5839-5851 (2014).
- 25 63. A. Singh, M. Wuthrich, B. Klein, M. Suresh, Indirect regulation of CD4 T-cell
26 responses by tumor necrosis factor receptors in an acute viral infection. *J Virol* **81**,
27 6502-6512 (2007).
- 28 64. S. Gupta, Tumor necrosis factor-alpha-induced apoptosis in T cells from aged
29 humans: a role of TNFR-I and downstream signaling molecules. *Exp Gerontol* **37**,
30 293-299 (2002).
- 31 65. S. Aggarwal, S. Gollapudi, S. Gupta, Increased TNF-alpha-induced apoptosis in
32 lymphocytes from aged humans: changes in TNF-alpha receptor expression and
33 activation of caspases. *J Immunol* **162**, 2154-2161 (1999).
- 34 66. N. Kaneko, H. H. Kuo, J. Boucau, J. R. Farmer, H. Allard-Chamard, V. S. Mahajan,
35 A. Piechocka-Trocha, K. Lefteri, M. Osborn, J. Bals, Y. C. Bartsch, N. Bonheur, T.
36 M. Caradonna, J. Chevalier, F. Chowdhury, T. J. Diefenbach, K. Einkauf, J. Fallon, J.
37 Feldman, K. K. Finn, P. Garcia-Broncano, C. A. Hartana, B. M. Hauser, C. Jiang, P.
38 Kaplonek, M. Karpell, E. C. Koscher, X. Lian, H. Liu, J. Liu, N. L. Ly, A. R. Michell,
39 Y. Rassadkina, K. Seiger, L. Sessa, S. Shin, N. Singh, W. Sun, X. Sun, H. J. Ticheli,
40 M. T. Waring, A. L. Zhu, G. Alter, J. Z. Li, D. Lingwood, A. G. Schmidt, M.
41 Lichterfeld, B. D. Walker, X. G. Yu, R. F. Padera, Jr., S. Pillai, G. Massachusetts
42 Consortium on Pathogen Readiness Specimen Working, Loss of Bcl-6-Expressing T
43 Follicular Helper Cells and Germinal Centers in COVID-19. *Cell* **183**, 143-157 e113
44 (2020).
- 45 67. J. Gu, E. Gong, B. Zhang, J. Zheng, Z. Gao, Y. Zhong, W. Zou, J. Zhan, S. Wang, Z.
46 Xie, H. Zhuang, B. Wu, H. Zhong, H. Shao, W. Fang, D. Gao, F. Pei, X. Li, Z. He, D.
47 Xu, X. Shi, V. M. Anderson, A. S. Leong, Multiple organ infection and the
48 pathogenesis of SARS. *J Exp Med* **202**, 415-424 (2005).
- 49 68. M. Koutsakos, L. C. Rowntree, L. Hensen, B. Y. Chua, C. E. van de Sandt, J. R.
50 Habel, W. Zhang, X. Jia, L. Kedzierski, T. M. Ashhurst, G. H. Putri, F. Marsh-

- 1 Wakefield, M. N. Read, D. N. Edwards, E. B. Clemens, C. Y. Wong, F. L. Mordant,
2 J. A. Juno, F. Amanat, J. Audsley, N. E. Holmes, C. L. Gordon, O. C. Smibert, J. A.
3 Trubiano, C. M. Hughes, M. Catton, J. T. Denholm, S. Y. Tong, D. L. Doolan, T. C.
4 Kotsimbos, D. C. Jackson, F. Krammer, D. I. Godfrey, A. W. Chung, N. J. King, S. R.
5 Lewin, A. K. Wheatley, S. J. Kent, K. Subbarao, J. McMahon, I. Thevarajan, T. H.
6 Nguyen, A. C. Cheng, K. Kedzierska, Integrated immune dynamics define correlates
7 of COVID-19 severity and antibody responses. *Cell Rep Med*, 100208 (2021).
- 8 69. R. Verity, L. C. Okell, I. Dorigatti, P. Winskill, C. Whittaker, N. Imai, G. Cuomo-
9 Dannenburg, H. Thompson, P. G. T. Walker, H. Fu, A. Dighe, J. T. Griffin, M.
10 Baguelin, S. Bhatia, A. Boonyasiri, A. Cori, Z. Cucunuba, R. FitzJohn, K. Gaythorpe,
11 W. Green, A. Hamlet, W. Hinsley, D. Laydon, G. Nedjati-Gilani, S. Riley, S. van
12 Elmland, E. Volz, H. Wang, Y. Wang, X. Xi, C. A. Donnelly, A. C. Ghani, N. M.
13 Ferguson, Estimates of the severity of coronavirus disease 2019: a model-based
14 analysis. *Lancet Infect Dis* **20**, 669-677 (2020).
- 15 70. M. N. Ramasamy, A. M. Minassian, K. J. Ewer, A. L. Flaxman, P. M. Folegatti, D. R.
16 Owens, M. Voysey, P. K. Aley, B. Angus, G. Babbage, S. Belij-Rammerstorfer, L.
17 Berry, S. Bibi, M. Bittaye, K. Cathie, H. Chappell, S. Charlton, P. Cicconi, E. A.
18 Clutterbuck, R. Colin-Jones, C. Dold, K. R. W. Emary, S. Fedosyuk, M. Fuskova, D.
19 Gbesemete, C. Green, B. Hallis, M. M. Hou, D. Jenkin, C. C. D. Joe, E. J. Kelly, S.
20 Kerridge, A. M. Lawrie, A. Lelliott, M. N. Lwin, R. Makinson, N. G. Marchevsky, Y.
21 Mujadidi, A. P. S. Munro, M. Pacurar, E. Plested, J. Rand, T. Rawlinson, S. Rhead,
22 H. Robinson, A. J. Ritchie, A. L. Ross-Russell, S. Saich, N. Singh, C. C. Smith, M. D.
23 Snape, R. Song, R. Tarrant, Y. Themistocleous, K. M. Thomas, T. L. Villafana, S. C.
24 Warren, M. E. E. Watson, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C. Gilbert, S. N.
25 Faust, A. J. Pollard, C. V. T. G. Oxford, Safety and immunogenicity of ChAdOx1
26 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults
27 (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet* **396**, 1979-
28 1993 (2021).
- 29 71. F. C. Zhu, X. H. Guan, Y. H. Li, J. Y. Huang, T. Jiang, L. H. Hou, J. X. Li, B. F.
30 Yang, L. Wang, W. J. Wang, S. P. Wu, Z. Wang, X. H. Wu, J. J. Xu, Z. Zhang, S. Y.
31 Jia, B. S. Wang, Y. Hu, J. J. Liu, J. Zhang, X. A. Qian, Q. Li, H. X. Pan, H. D. Jiang,
32 P. Deng, J. B. Gou, X. W. Wang, X. H. Wang, W. Chen, Immunogenicity and safety
33 of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults
34 aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
35 *Lancet* **396**, 479-488 (2020).
- 36 72. A. Silva-Cayetano, W. S. Foster, S. Innocentin, S. Belij-Rammerstorfer, A. J.
37 Spencer, O. T. Burton, S. Fra-Bido, J. Le Lee, N. Thakur, C. Conceicao, D. Wright, J.
38 Barrett, N. Evans-Bailey, C. Noble, D. Bailey, A. Liston, S. C. Gilbert, T. Lambe, M.
39 A. Linterman, A Booster Dose Enhances Immunogenicity of the COVID-19 Vaccine
40 Candidate ChAdOx1 nCoV-19 in Aged Mice. *Med (N Y)*, (2020).
- 41 73. A. T. Widge, N. G. Roupheal, L. A. Jackson, E. J. Anderson, P. C. Roberts, M.
42 Makhene, J. D. Chappell, M. R. Denison, L. J. Stevens, A. J. Pruijssers, A. B.
43 McDermott, B. Flach, B. C. Lin, N. A. Doria-Rose, S. O'Dell, S. D. Schmidt, K. M.
44 Neuzil, H. Bennett, B. Leav, M. Makowski, J. Albert, K. Cross, V. V. Edara, K.
45 Floyd, M. S. Suthar, W. Buchanan, C. J. Luke, J. E. Ledgerwood, J. R. Mascola, B. S.
46 Graham, J. H. Beigel, R. N. A. S. G. m, Durability of Responses after SARS-CoV-2
47 mRNA-1273 Vaccination. *N Engl J Med*, (2020).
- 48 74. M. Prendecki, C. Clarke, J. Brown, A. Cox, S. Gleeson, M. Guckian, P. Randell, A.
49 D. Pria, L. Lightstone, X. N. Xu, W. Barclay, S. P. McAdoo, P. Kelleher, M.

- 1 Willicombe, Effect of previous SARS-CoV-2 infection on humoral and T-cell
2 responses to single-dose BNT162b2 vaccine. *Lancet*, (2021).
- 3 75. D. A. Collier, I. A. T. M. Ferreira, R. Datir, B. Meng, L. Bergamaschi, C.-N. B. C.-.
4 Collaboration, A. Elmer, N. Kingston, B. Graves, K. G. C. Smith, J. R. Bradley, P. A.
5 Lyons, L. Ceron-Gutierrez, G. Barcenas-Morales, R. Doffinger, M. R. Wills, R. K.
6 Gupta, Age-Related Heterogeneity in Neutralising Antibody Responses to SARS-
7 CoV-2 Following BNT162b2 Vaccination. . *Available at SSRN*: .
- 8 76. K. Lederer, D. Castano, D. Gomez Atria, T. H. Oguin, 3rd, S. Wang, T. B. Manzoni,
9 H. Muramatsu, M. J. Hogan, F. Amanat, P. Cherubin, K. A. Lundgreen, Y. K. Tam, S.
10 H. Y. Fan, L. C. Eisenlohr, I. Maillard, D. Weissman, P. Bates, F. Krammer, G. D.
11 Sempowski, N. Pardi, M. Locci, SARS-CoV-2 mRNA Vaccines Foster Potent
12 Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody
13 Generation. *Immunity* **53**, 1281-1295 e1285 (2020).
- 14 77. A. Ellebedy, J. Turner, J. O'Halloran, E. Kalaidina, W. Kim, A. Schmitz, T. Lei, M.
15 Thapa, R. Chen, J. Case, F. Amanat, A. Rauseo, A. Haile, M. Klebert, T. Suessen, W.
16 Middleton, F. Krammer, S. Teefey, M. Diamond, R. Presti, X. Xie, P. Shi, SARS-
17 CoV-2 mRNA vaccines induce a robust germinal centre reaction in humans. *Research*
18 *Square 'In review'*, (2021).
- 19 78. E. F. Wallin, E. C. Jolly, O. Suchanek, J. A. Bradley, M. Espeli, D. R. Jayne, M. A.
20 Linterman, K. G. Smith, Human T-follicular helper and T-follicular regulatory cell
21 maintenance is independent of germinal centers. *Blood* **124**, 2666-2674 (2014).
- 22 79. J. Wang, S. P. Hilchey, O. Hyrien, N. Huertas, S. Perry, M. Ramanunnair, D.
23 Bucher, M. S. Zand, Multi-Dimensional Measurement of Antibody-Mediated
24 Heterosubtypic Immunity to Influenza. *PLoS One* **10**, e0129858 (2015).
- 25 80. G. L. Chen, E. W. Lamirande, H. Jin, G. Kemble, K. Subbarao, Safety,
26 immunogenicity, and efficacy of a cold-adapted A/Ann Arbor/6/60 (H2N2) vaccine in
27 mice and ferrets. *Virology* **398**, 109-114 (2010).
- 28 81. D. Kim, B. Langmead, S. L. Salzberg, HISAT: a fast spliced aligner with low
29 memory requirements. *Nat Methods* **12**, 357-360 (2015).
- 30 82. Y. Liao, G. K. Smyth, W. Shi, The R package Rsubread is easier, faster, cheaper and
31 better for alignment and quantification of RNA sequencing reads. *Nucleic Acids Res*
32 **47**, e47 (2019).
- 33 83. D. Risso, J. Ngai, T. P. Speed, S. Dudoit, Normalization of RNA-seq data using factor
34 analysis of control genes or samples. *Nat Biotechnol* **32**, 896-902 (2014).
- 35 84. W. Huber, A. von Heydebreck, H. Sultmann, A. Poustka, M. Vingron, Variance
36 stabilization applied to microarray data calibration and to the quantification of
37 differential expression. *Bioinformatics* **18 Suppl 1**, S96-104 (2002).
- 38 85. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion
39 for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 40 86. A. A. Sergushichev, An algorithm for fast preranked gene set enrichment analysis
41 using cumulative statistic calculation. *bioRxiv*, (2016).
- 42 87. E. Lee, H. Y. Chuang, J. W. Kim, T. Ideker, D. Lee, Inferring pathway activity
43 toward precise disease classification. *PLoS Comput Biol* **4**, e1000217 (2008).
- 44 88. L. M. Franco, K. L. Bucasas, J. M. Wells, D. Nino, X. Wang, G. E. Zapata, N. Arden,
45 A. Renwick, P. Yu, J. M. Quarles, M. S. Bray, R. B. Couch, J. W. Belmont, C. A.
46 Shaw, Integrative genomic analysis of the human immune response to influenza
47 vaccination. *Elife* **2**, e00299 (2013).
- 48 89. L. Gautier, L. Cope, B. M. Bolstad, R. A. Irizarry, affy--analysis of Affymetrix
49 GeneChip data at the probe level. *Bioinformatics* **20**, 307-315 (2004).

- 1 90. D. A. Bolotin, S. Poslavsky, I. Mitrophanov, M. Shugay, I. Z. Mamedov, E. V.
2 Putintseva, D. M. Chudakov, MiXCR: software for comprehensive adaptive immunity
3 profiling. *Nat Methods* **12**, 380-381 (2015).
- 4 91. M. Shugay, D. V. Bagaev, M. A. Turchaninova, D. A. Bolotin, O. V. Britanova, E. V.
5 Putintseva, M. V. Pogorelyy, V. I. Nazarov, I. V. Zvyagin, V. I. Kirgizova, K. I.
6 Kirgizov, E. V. Skorobogatova, D. M. Chudakov, VDJtools: Unifying Post-analysis
7 of T Cell Receptor Repertoires. *PLoS Comput Biol* **11**, e1004503 (2015).
- 8 92. A. Alpert, Y. Pickman, M. Leipold, Y. Rosenberg-Hasson, X. Ji, R. Gaujoux, H.
9 Rabani, E. Starosvetsky, K. Kveler, S. Schaffert, D. Furman, O. Caspi, U.
10 Rosenschein, P. Khatri, C. L. Dekker, H. T. Maecker, M. M. Davis, S. S. Shen-Orr, A
11 clinically meaningful metric of immune age derived from high-dimensional
12 longitudinal monitoring. *Nat Med* **25**, 487-495 (2019).
- 13 93. P. Angerer, L. Haghverdi, M. Buttner, F. J. Theis, C. Marr, F. Buettner, destiny:
14 diffusion maps for large-scale single-cell data in R. *Bioinformatics* **32**, 1241-1243
15 (2016).
- 16 94. L. Haghverdi, M. Buttner, F. A. Wolf, F. Buettner, F. J. Theis, Diffusion pseudotime
17 robustly reconstructs lineage branching. *Nat Methods* **13**, 845-848 (2016).
- 18 95. R. Kolde, pheatmap: Pretty Heatmaps. *R package version 1.0.10*, ((2018)).
19

[Figure 1]




Figure 1: Robust hemagglutinin-specific CD4⁺ T cells response to seasonal influenza vaccination.

a) Overview of cohort characteristics, vaccination strains and immune variables measured before (d0), seven days (d7) and 42 days (d42) after seasonal influenza vaccination. b) IgG responses to Haemagglutinin proteins from vaccine influenza strains measured by Luminex. Dashed line indicates limit of detection in Luminex assay. c) Log₂ fold change versus -log₁₀ FDR-adjusted p-value of Flu HA Luminex, Cytokine Luminex, B cell and CD4⁺ T cell immunophenotyping parameters before and after vaccination at indicated time-points for Cohort 1. Dashed line represents the p-value cut off at FDR-adjusted p=0.05. d) Representative flow cytometry plots of HA₂₅₇₋₂₇₆HLADR*0701 staining on CD4⁺CD45RA⁻ cells, gate corresponds to HA-specific TET⁺ T cells, and e) the frequency of HA-specific TET⁺ T cells among all CD4⁺CD45RA⁻ cells on d0 compared to d7. f) Representative ICOS staining, and g) the percentage of ICOS⁺ cells among HA-specific TET⁺ T cells on d0 and d7. h) CXCR5 and PD1 staining on HA-specific TET⁺ T cells on d0 and d7, gate corresponds to ‘TET⁺cTfh’ T cells, and i) the percentage of cTfh cells among HA-specific TET⁺ T cells on d0 and d7 for each cohort. In parts d-i; Cohort 1 n= 16; Cohort 2 n = 19. Paired p-values determined using Wilcoxon signed rank-test.

[Figure 2]




Figure 2: Circulating HA-specific Tfh cells correlate with vaccine IgG response.

a) Overview of correlation analysis between A.Cali09 IgG response at day 42 (minus d0 baseline titer, d42-d0) and immune variables for Cohort 1, Cohort 2 and both cohorts combined (All). b) Correlations for Flu HA Luminex IgG and hemagglutination inhibition (HAI) titres at d0, d7 and d42, and at d7 and d42 after subtracting each individuals d0 baseline value (d7-d0, d42-d0). c) Correlations for serum cytokines measured by Luminex at d0, d7 and d42, and at d7 and d42 after subtracting each individuals d0 baseline value (d7-d0, d42-d0). d) Correlations for B cell, CD4⁺ T cell and HA-specific CD4⁺ T cell variables at d0, d7 and d7 after subtracting each individuals d0 baseline value (d7-d0). e) Correlation between vaccine-induced A.Cali09 IgG at d42 with selected immune parameters in both Cohort 1 and Cohort 2 (n=37). Dot color corresponds to the cohort (black = Cohort 1, grey = Cohort 2). Coefficient (Rho) and p-value determined using Spearman's correlation, and line represents linear regression fit.

[Figure 3]




Figure 3: HA-specific cTfh response to flu vaccination includes recalled and public TCR clonotypes

a) Overview of cell types and sample sizes that were sequenced d0 and d7 at each cohort. d0 median = 45 cells (6-258); d7 median = 88 cells (5-1000). b) Representative pie charts of the proportions unique T cell receptor (TCR) β -chain clonotypes for participants 408S and 425L at d0 and d7. Inset numbers indicate the number of cells sequenced and number of unique TCR β clonal sequences retrieved. c) Normalised Shannon Wiener index of TCR β and TCR α repertoire diversity at d0 TET⁺ T cells and d7 TET⁺ cTfh cells, for both cohorts combined. d) The number of dominant TCR β clones (frequency of >10%) for each individual in d0 and d7 sequenced cells for both cohorts combined. e) TCR β clonotype frequencies at d0 and d7 in combined dataset of 15 individuals with paired d0 and d7 samples (1772 clones in total). Each dot represents a clonotype, size corresponds to d7 frequency. Red color indicates “recalled” clones that were measured at both time-points, and solid lines indicate where clones are only detected at a single time-point. f) The number of ‘recalled’ TCR β clones per individual (present at both d0 and d7), and g) the aggregate frequency of d7 TET⁺ cTfh TCR β clones that were recalled for each individual (n= 15). h) The log₁₀ d0 frequency of each “recalled” or “unique” (present at d0 only) clone (n = 102 recalled, n = 663 unique clones). i) The number and j) combined frequency of public clonotypes per individual at each time point, cohorts 1 and 2 combined (d0 n= 25, d7 n = 20). Public clonotypes were defined as TCR β sequences with identical v, d, j genes and CDR3 amino acid sequence shared between at two or more samples from the same time point. k) TRBJ and TRBV gene usage among the 26 HA-specific public clonotypes, separated by HLADR genotype and time-point. All p-values were calculated using a Mann-Whitney *U* test.

[Figure 4]




Figure 4: Vaccination induced circulating Tfh cells share a common transcriptional signature with lymph node Tfh cells.

a) Principal component analysis of 1000 genes with the largest variance in sequenced cells from d0 TET⁺ cells (shown in grey) and d7 TET⁺ cTfh cells (shown in green), for each cohort separately. b) Venn diagram of the 684 significantly differentially expressed (DE) genes in d7 TET⁺cTfh cells (relative to d0) in both cohorts, and the overlap with a signature of human lymph node germinal centre (GC) Tfh cells where genes had the same direction of expression. DE genes determined using DESeq2, and had adjusted p-value <0.1 and fold change of 2. Up and down regulated genes represented by red and blue colours, respectively. c) Heatmaps of gene signatures determined in (b) for each cohort, with representative genes labelled. d) Venn diagram of the 10 consistently enriched Hallmarks pathways in d7 TET⁺cTfh cells relative to d0 TET⁺ cells in both cohorts, and the overlap with positively or negatively enriched gene sets in LN GC Tfh cells compared to non-Tfh CD4⁺ cells. Significant pathways were determined using gene set enrichment analysis (GSEA) and had adj p-value <0.1 and normalised enrichment score of >1 or <-1. Up and down regulated pathways are represented by arrows and red and blue colours, respectively. e) Bubble plots showing the normalised enrichment scores for significantly enriched pathways for d7 TET⁺ cTfh cells versus d0 TET⁺ cells in each cohort, and LN GC Tfh cells vs non-Tfh cells, with positive and negative scores indicating positive and negative enrichment, respectively, in TET⁺ Tfh and/or GC Tfh compared to their non-Tfh comparator. Circle colour represents the type of comparison, and size represents the adjusted p-value.

[Figure 5]




Figure 5: Impaired vaccination immune trajectory in older individuals.

a) Overview of age-groups and sample sizes for each cohort. b) IgG responses to HA proteins from vaccine influenza strains measured by Luminex for each age-group. c) Diffusion map dimensionality reduction of 122 samples from both cohorts combined using scaled values for 23 immune parameters and the diffusion-pseudotime algorithm (d0 18-36yo n= 27; d0 65+yo n= 32; d7 18-36yo n= 30; d7 65+yo n=33). Each dot represents a sample, shape represents time point (d0 = squares, d7 = circles), and colour either the pseudotime ‘vaccination trajectory’ output value or age-group category. Diffusion components (DC) 1 and 2 shown. d) Vaccination trajectory values for sample in each age category from both cohorts combined, with p-values calculated using Dunn’s post hoc test. e) Spearman correlation coefficients for the 11 parameters that significantly correlated with the vaccination trajectory variable ($p_{adj} < 0.05$). f-h) Heatmap of FDR-adjusted p-values from Mann-Whitney U test comparing immune parameters between age-groups for Cohort 1, Cohort 2 and both cohorts combined (All), at d0, d7 and d42, and at d7 and d42 after subtracting each individuals d0 baseline value (d7-d0, d42-d0) for f) Flu HA Luminex and HAI, g) Cytokine Luminex, h) B cells, CD4⁺ T cells and HA-specific CD4⁺ T cells. Colour corresponds to p-value and the direction of change. i) The percentage of CXCR5⁺PD1⁺⁺ cTfh cells and j) TET⁺ cTfh cells for each age-group and each cohort, with p-values calculated by Mann-Whitney U test (Cohort 1 18-36yo n= 17, 65+yo n=17; Cohort 2 18-36yo n=20, 65+yo n=21).

[Figure 6]




Figure 6: Impaired induction of Tfh transcriptional programs and aberrant inflammatory signatures in HA-specific cTfh cells from older individuals.

a) Overview of sample numbers and cell types sequenced at d0 and d7 for each cohort and each age-group. Dark and light green dots indicate d7 Tet⁺ cells sequenced from Cohort 2 only. b) Normalised Shannon Wiener diversity index of TCR β clonotypes for each cohort, time-point and cell type. Each dot represents a sequenced sample. c) Normalised Shannon Wiener diversity index of TCR β clonotypes in d7 Tet⁺ cells from Cohort 2. d) The number of TCR β clones per individual in d7 Tet⁺ cTfh cells recalled from d0 Tet⁺ cells, and e) combined frequency of the recalled clones among d7 Tet⁺cTfh cells for each age-group (n= 15 in each age-group, both cohorts combined). P-values calculated using Mann-Whitney U test. f) Frequency of TCR β clones present in paired samples of d7 Tet⁺ and d7 Tet⁺cTfh cells. Each dot represents a clonotype, dot color indicates age-group, and dot size corresponds the frequency in d7 Tet⁺ cells. Lines represent linear regression, and statistics determined using Pearson correlation. g) Principal component (PC) analysis of the 684 genes differentially expressed (DE) between d0 and d7 in samples from 18-36 year olds applied to d0 and d7 samples from both age-groups and cohorts. Histograms show the distribution of PC1 values for each group, with p-value calculated between age-groups for d7 samples by Mann Whitney U test. h) Bubble plots of 7 Hallmarks pathways that are upregulated in d7 Tet⁺cTfh cells in samples from 65+year-old compared to 18-36-year-old individuals, sub-divided by which pathways were previously identified as negatively enriched in lymph node germinal centre Tfh cells. Positive scores indicate positive enrichment in Tet⁺cTfh cells from older donors. Circle colour represents the cohort, size represents the adjusted p-value. i) Inflammation, TNF and IL2 gene signature scores in HA-specific T cells at different time-points and age-groups, cohorts 1 and 2 combined (d0 18-36yo n= 20, d0 65+yo n = 20; d7 18-36yo n= 22; 65+yo n = 19). p-value calculated using Dunn's post-hoc test.

[Figure 7]




Figure 7: Gene signatures of TNF, IL-2, and inflammation associate with impaired antibody and Tfh cell responses to influenza vaccination.

a) Correlation between cTfh Tet⁺ cells and Inflammation, TNF or IL2 gene signatures scores in d7 Tet⁺cTfh cells. b) Correlation between A.Cali09 IgG titre (d42-d0) and Inflammation, TNF or IL2 gene signatures scores in d7 Tet⁺cTfh cells. c) Correlation between A.Cali09 IgG titre (d28-d0) and Inflammation, TNF or IL2 gene signatures scores determined from microarray data of peripheral blood mononuclear cells on d0 or d7 after seasonal influenza vaccination from publicly available datasets (n= 50 total; 26-41yo n=18 , 66-86yo = 32)(8). Correlation coefficients and p-values calculated using Spearman's Correlation coefficient. Solid line represents linear regression fit. Color corresponds to age-group (Green = younger people; aqua = older people).